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ABSTRACT 




Human and murine diabetes is characterized by pancreatic β-cell 
dedifferentiation, a process in which β-cells lose expression of markers of maturity and 
gain those of endocrine progenitors. Failing β-cells inappropriately metabolize lipids 
over carbohydrates and exhibit impaired mitochondrial oxidative phosphorylation. 
Therefore, pathways involved in mitochondrial fuel selection and catabolism may 
represent potential targets for the prevention or reversal of dedifferentiation.  
In chapter I of this dissertation, we isolated and functionally characterized failing 
β-cells from various experimental models of diabetes. We found a striking enrichment in 
the expression of aldehyde dehydrogenase 1 isoform A3 (Aldh1a3) as β-cells become 
dedifferentiated. Flow-sorted Aldh1a3-expressing (ALDH+) islet cells demonstrate 
impaired glucose-induced insulin secretion, are depleted of Foxo1 and MafA, and 
include a Neurogenin3-positive subset. RNA sequencing analysis demonstrated that 
ALDH+ cells are characterized by: (i) impaired oxidative phosphorylation and 
mitochondrial complex I, IV, and V; (ii) activated RICTOR; and (iii) progenitor cell 
markers. We propose that impaired mitochondrial function marks the progression from 
metabolic inflexibility to dedifferentiation in the natural history of β-cell failure. 
In chapter II of this dissertation, we report that cytochrome b5 reductase 3 
(Cyb5r3) is a FoxO1-regulated mitochondrial oxidoreductase critical to β cell function. 
Expression of Cyb5r3 is greatly decreased in multiple murine models of diabetes, and in 
vitro Cyb5r3 knockdown leads to increased ROS generation and impairment of 
respiration, mitochondrial function, glucose-stimulated insulin secretion, and calcium 
mobilization. In vivo, mice with β-cell-specific ablation of Cyb5r3 (B-Cyb5r3) display 
impaired glucose tolerance with decreased insulin secretion, and their islets have 
significantly lower basal respiration and glucose-stimulated insulin secretion. B-Cyb5r3 
β-cells lose expression of Glut2, MafA, and Pdx1 expression despite a compensatory 
increase in FoxO1 expression. Our data suggest that Cyb5r3 is a critical mediator of 
FoxO1’s protective response in β-cells, and that loss of Cyb5r3 expression is an early 
event in β-cell failure. 
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LIST OF FIGURES 
Fig. 1 Increased levels and activity of ALDH1A3 in diabetic mice. a, Western blot of 
ALDH1A3 in islets isolated from different models of wild-type and diabetic mice. “DIO” 
denote diet-induced obese mice fed 60% fat diet. The lower molecular weight band in 
young (3-month-old) mice is a non-specific band commonly observed with Aldh1a3 
immunodetection. b-c, All-trans (b) and 9-cis retinoic acid (c) in the whole pancreas of 
control and diabetic mice. Shaded bars: db/db mice and their wild-type controls; filled 
bars: Pdx-cre Foxo knockout mice and their wild-type controls (n=5 for each group). 
One asterisk indicates p<0.05 by one-factor ANOVA. 
 
Table 1. Comparison of the top 10 transcripts in two models of Foxo knockout β 
cells. List of the 10 top overexpressed genes from RNA sequencing analysis of β cells 
isolated from β cell-specific and pan-pancreatic Foxo triple Foxo knockouts compared to 
their relevant wild-type controls. 
 
Fig. 2 Localization of ALDH1A3 in mouse islets. a, ALDH1A3 immunoreactivity in 
islets from normal and diabetic GIRKO mice 1. b, Co-immunostaining of ALDH1A3 and 
insulin or glucagon, somatostatin, and PP in db/db, GIRKO, and Pdx1-cre-driven Foxo 
knockout mice. c-e, Co-immunostaining of ALDH1A3 with MafA (c), Pdx1 (d), or Nkx6.1 
(e). ALDH+/Nkx6.1– cells are indicated by the white arrows. MafA/ALDH1A3 (c) and 
Nkx6.1/ALDH1A3 (d) stainings were performed on consecutive sections, whereas the 
NKX6.1/ALDH1A3 staining in (e) was performed on the same section. f-g, Co-
immunohistochemistry of ALDH1A3 with progenitor cell markers, L-myc (f) and 
	 iii	
Neurogenin3 (g). ALDH1A3+/ Neurog3+ cells are indicated by the white arrows. 
Neurog3/ALDH1a3 stainings were performed on consecutive sections. To better assess 
Neurog3/ALDH1A3-positive cells, we provide two representative sections from Foxo 
knockout mice. 
 
Fig. 3 ALDH gain-of-function in β cells. a, Effect of Foxo1 overexpression on Aldh1a3 
mRNA in Min6 cells. Foxo-DN is a truncated mutant that is unable to drive gene 
expression and competes with endogenous Foxo for DNA binding. Foxo-DBD is a 
mutant unable to bind the Foxo response element, but can still function as a coregulator 
of gene expression 2. b, Western blot analysis of ALDH1A3 levels following lentiviral 
transduction in Min6 cells. c, Gene expression in Min6 cells stably-expressing GFP or 
ALDH1a3. d, Insulin secretion expressed as fold-increase from 5 to 20 mM glucose in 
MIN6 cells expressing either GFP or ALDH1A3 (n=8). e, Insulin secretion in primary 
islets from C57Bl/6J mice expressing either GFP or ALDH1A3 adenovirus (n=3).  f, 
Insulin secretion (expressed as in panel d) in islets isolated from db/db mice and their 
wild-type controls following treatment with the ALDH inhibitor DEAB at the doses 
indicated (n=4). Each experiment was performed with pooled islets from 5 mice per 
genotype. g, Area under the curve of oxygen consumption rates measured in Min6 cells 
stably expressing either GFP or ALDH1A3 (n=4 per group). One asterisk indicates 
p<0.05 by one-factor ANOVA. 
 
Fig. 4 Isolation and characterization of ALDH+ cells. a, Enrichment procedure to 
isolate ALDH-expressing islet cells. β cells are labeled red by Rip-cre-activated Tomato. 
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Cells are incubated with aldefluor, and selected for tomato and aldefluor, yielding 
ALDH– (low) and ALDH+ (high) cells. b-c, Experimental validation. Islets from 6-month-
old β cell-specific (Rip-cre) Foxo knockouts and littermate controls were sorted as 
described. The different circles denote the three cell populations used in further studies: 
RFP–ALDH–, RFP+ALDH–, and RFP+ALDH+. d, Quantification of RFP+ALDH+ cells in 
repeated sorts (n=5) of wild-type and Rip-Foxo knockout animals. e, Insulin secretion in 
RFP–ALDH– (GFP_FITC, PE TR subset 2), RFP+ALDH– (GFP_FITC, PE TR subset), 
and RFP+ALDH+ (GFP_FITC, PE TR subset 1) cells isolated from Rip-Foxo knockout 
mice (n=3). f-n, qPCR analysis of selected transcripts in the different fractions isolated 
from islet cell preparations. One asterisk indicates p<0.05 by one-factor ANOVA. 
 
Fig. 5 Comprehensive analysis of ALDH isoform expression in flow-sorted ALDH+ 
and ALDH– cells. a, Data from RNA sequencing of all ALDH transcripts are 
represented as column Z-scores, with red indicating high expression and blue indicating 
low expression. Each row represents a different ALDH isoform, and each column an 
individual population from a single mouse used for analysis. RFP+ALDH–: JD001 
through JD014, and RFP+ALDH+: JD003 through JD015. Aldh1a3 is boxed for 
reference. b, Model of the relationship between changes in Foxo levels and gene 
expression signature of ALDH+ cells.  
 
Table 2. Curated list of differentially expressed transcripts in wild-type ALDH– vs. 
ALDH+ cells. This table lists a subset of genes differentially expressed between ALDH– 
and ALDH+ cells, arranged by functional category.  
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Table 3. Pathway analysis of RNA sequencing in wild-type and Foxo knockout β 
cells. The table summarizes top pathways from transcriptome analysis of ALDH– vs. 
ALDH+ cells.  
 
Table 4. Progenitor-like features of ALDH+ cells. Z-score analysis of transcriptional 
networks involved in pancreas development in ALDH+ cells. 
 
Table 5. Top 25 differentially expressed transcripts in ALDH+ cells from wild-type 
and Foxo knockout mice. This table lists a subset of genes differentially expressed 
between wild-type and triple Foxo-deficient ALDH+ cells, arranged by p-value.  
 
Table 6. Overview of key differential changes in transcript profile of wild-type and 
Foxo knockout ALDH+ cells. Category list of principal genes altered in ALDH+ cells as 
a function of Foxo genotype. Upward arrows indicate genes with increased expression, 
downward arrows indicate genes with decreased expression. Arrows in the Foxo 
column indicate that the change is specific to Foxo knockout ALDH+ cells.  
 
CHAPTER II 
Fig. 6 Expression of Cyb5r3 in Islets from Diabetic Mice (A) Cyb5r3 mRNA levels in 
Aldh-low (Aldh-) and Aldh-high (Aldh+) β-cells from RIP-Cre+ (Ctrl) vs. RIP-Cre+ 
FoxO1/3/4fl/fl (β-FoxO) mice (n=5 per group).  (B) Co-Immunofluorescence of insulin 
(red), Aldh1a3 (blue), Cyb5r3 (green), and DAPI (white) in control vs. β-FoxO mice. (C) 
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ChIP-qPCR at the Cyb5r3 promoter using anti-FoxO1 or control antibody in Min6 cell 
lysates. (D) Cyb5r3 expression in Min6 cells treated with adenovirus expressing GFP, 
constitutively active FoxO1-ADA, or dominant negative FoxO1-DN256. All data in all 
panels are presented as means ± SEM. **p < 0.05, **p < 0.01, ***p < 0.001 by Student’s 
t-test. 
 
Fig. 7 Effects of Cyb5r3 Knockdown on Insulin Secretion, Respiration, ETC, 
NAD/NADH and ROS Generation. (A) Insulin secretion in Min6 cells treated 
with Ad-shCyb5r3 or Ad-shScramble at indicated glucose concentrations. (B) 
Basal respiration in Min6 cells stably expressing GFP, shCyb5r3, or shCyb5r4. 
(C-F) Mitochondrial ETC complex I-IV activity in isolated mitochondria from Ad-
shCyb5r3 or Ad-shScr-treated Min6 cells. (G) ROS levels in Min6 cells treated 
with Ad-shCyb5r3 or Ad-shScr with or without 0.5mM palmitate. (H) NAD/NADH 
ratio and (I) NADH levels in Min6 cells treated with Ad-shScr, Ad-shCyb5r3, or 
Ad-Cyb5r3-GFP. (J) Lactate levels in Min6 cells treated with Ad-shCyb5r3 or Ad-
shScr following incubation with 0.5mM palmitate. All data in all panels are 
presented as means ± SEM. **p < 0.05, **p < 0.01, ***p < 0.001 by Student’s t-
test. 
 
Fig. 8 Effects of Cyb5r3 Knockdown in Primary Islets. (A) Glucose-stimulated 
insulin secretion and (B) insulin content in wildtype islets treated with Ad-
shCyb5r3 or Ad-shScr. (C) Representative calcium flux traces from Insulin2-Gfp 
β-cells treated with Ad-shCyb5r3 or Ad-shScr measured by Fura2AM 
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fluorescence (n=10-20 per group). Black arrow denotes point at which perfusion 
changed from 2.8mM to 16.8mM glucose. Red arrow denotes change from 
16.8mM glucose to 40mM KCl. (D) Averaged maximal peak heights of the 
340/380 ratio from the same experiment (n=3 plates per treatment, with 10-30 
beta cells counted per plate). All data in all panels are presented as means ± 
SEM. **p < 0.05, **p < 0.01, ***p < 0.001 by Student’s t-test. 
 
Fig. 9 Islet Cell Markers in Pancreata from 2-month-old mice. (A) Insulin 
(red), Cyb5r3 (green), and DAPI (blue) immunostaining in B-Cyb5r3 vs. RIP-Cre+ 
control mice. (B) Insulin (red), glucagon (green), somatostatin with pancreatic 
polypeptide (SMS+PP) (Blue), and DAPI (white). (C) Insulin (red), Glut2 (green), 
and DAPI (blue). (D) Insulin (red), MafA (green), and DAPI (blue). (E) Insulin 
(red), Cyb5r3 (green), Pdx1 (blue), and DAPI (white).  
 
Fig. 10 Islet Cell Markers in Pancreata from 6-month-old mice. (A) Insulin 
(red), glucagon (green), somatostatin with pancreatic polypeptide (SMS+PP) 
(Blue), and DAPI (white) immunostaining in B-Cyb5r3 vs. RIP-Cre+ control mice. 
(B) Insulin (red), Glut2 (green), and DAPI (blue). (C) Insulin (red), MafA (green), 
and DAPI (blue). (D) Insulin (red), Cyb5r3 (green), Pdx1 (blue), and DAPI (white). 
(E) FoxO1 (green) and DAPI (blue).  
 
Fig. 11 Metabolic Characterization of B-Cyb5r3 Mice. (A) Intraperitoneal 
glucose tolerance test (IPGTT) in 4-month-old female and (B) male B-Cyb5r3 
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mice vs. RIP-Cre+ controls. (C) 1hr refed serum insulin levels normalized to 
insulin after 4hr-fast in female B-Cyb5r3 mice. (D) Insulin tolerance test in 4-
month-old female and (E) male B-Cyb5r3 mice vs. RIP-Cre+ controls. (F) Blood 
glucose in female B-Cyb5r3 vs. RIP-Cre+ control mice fed high fat diet for 1 
week. (G) IPGTT in 4-month-old female and (H) male B-Cyb5r3 mice vs. RIP-
Cre+ controls fed HFD for 8 weeks. (I) Insulin levels 15 and 30 minutes during 
IPGTT normalized by fasting levels in 4-month-old B-Cyb5r3 mice vs. RIP-Cre+ 
controls, both fed HFD for 8 weeks. All data in all panels are presented as means 
± SEM. **p < 0.05, **p < 0.01, ***p < 0.001 by Student’s t-test.  
 
Fig. 12 Hyperglycemic Clamps (A) Blood glucose, (B) body weight, (C-D) 
glucose infusion rate, and (E-F) serum insulin in female B-Cyb5r3 vs. RIP-Cre+ 
control mice during the clamp. (D) and (F) are AUC quantifications of (C) and (E), 
respectively. All data in all panels are presented as means ± SEM. **p < 0.05, **p 
< 0.01, ***p < 0.001 by Student’s t-test. 
 
Fig. 13 B-Cyb5r3 Islet Function. (A) Glucose- and (B) secretagogue-stimulated 
insulin secretion in primary islets from B-Cyb5r3 vs. RIP-Cre+ controls (n=4 
samples each containing 5 islets from 3 mice for GSIS, n=6 wells each 
containing 70 islets for islet respiration). (C) Time course of oxygen consumption 
rate measured in primary islets from B-Cyb5r3 vs. RIP-Cre+ controls. “Glucose” 
indicates the addition of 25mM glucose media. Oligomycin inhibits ATP synthase, 
FCCP is an uncoupler, and rotenone is an inhibitor of complex I. Islets from 5 
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mice were pooled in n=9 wells per genotype, with each well containing ~70 islets. 
All data in all panels are presented as means ± SEM. **p < 0.05, **p < 0.01, ***p 
< 0.001 by Student’s t-test. 
 
Supplemental Fig.1 Cyb5r3 Expression in Islets of Multiple Murine Models of 
Diabetes or Insulin Resistance. (A) Insulin (green), Cyb5r3 (blue), and DAPI (white) 
expression in Glut4-Cre Insulin Receptor Knockout (GIRKO) mice compared to Glut4-
Cre+ Controls. (B) Insulin (red), Cyb5r3 (green), Pdx1 (blue), and DAPI (white) staining 
in mice fed normal chow or HFD for 20 weeks (C) Insulin (red), Cyb5r3 (green), Pdx1 
(blue), and DAPI (white).staining in S961-treated (1wk) mice. 
 
Supplemental Fig. 2 Knockdown Efficiency of shCyb5r3 Adenovirus. (A) 
Cyb5r3 mRNA levels in Min6 cells treated with shCyb5r3 vs. shScramble at 
varying MOIs of shCyb5r3 adenovirus. (B) Cyb5r4 mRNA expression in the same 
samples. (C) Densitometry of Cyb5r3 protein expression in samples treated with 
shScr vs. varying MOIs of shCyb5r3 adenovirus. (D) Western blot used for 
densitometry shown in (C). Rat Ins1 cells were used as a negative control for the 
mouse-specific shCyb5r3 sequence. 
 
Supplemental Fig. 3 Metabolic Phenotyping Experiments Performed on B-
Cyb5r3 mice. (A-B) Magnetic Resonance Imaging (MRI) of B-Cyb5r3 vs. RIP-
Cre+ control mice fed (A) normal chow and (B) HFD. (C-D) Oral glucose 
tolerance test (OGTT) of 4-month old B-Cyb5r3 (C) female and (D) male mice fed 
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normal chow. (E) Fasting and refed serum triglycerides and non-esterified free 
fatty acids (NEFAs) in male and female B-Cyb5r3 mice fed normal chow. (D) 
IPGTT in S961-treated B-Cyb5r3 and RIP-Cre+ control mice (5 months old, n=6 
per group).  
 
Supplemental Fig. 4 Islet Cyb5r3 Staining and GTT in Male B-Cyb5r3 mice. 
(A) Insulin (red), Cyb5r3 (green), Pdx1 (blue), and DAPI (white) immunostaining 
in B-Cyb5r3 vs. RIP-Cre+ control mice. (B) IPGTT in 8-month-old male B-Cyb5r3 
mice.  
 
Supplemental Fig. 5 Islet Cell Quantification in B-Cyb5r3 Mice. (A) Insulin, 
glucagon, and somatostatin+pp area normalized to total islet area as determined 
by immunohistochemistry. Data shown for 2 month and 6 month old B-Cyb5r3 
mice vs. RIP-Cre+ controls. 
 
Supplemental Fig. 6 Progenitor Cell Marker Immunohistochemistry in B-
Cyb5r3 Mice (A) Insulin (red), Neurog3 (green), and DAPI (white) 
immunostaining in B-Cyb5r3 vs. RIP-Cre+ control mice. (B) Insulin (red), Aldh1a3 
(green), and DAPI (white).  
 




I am grateful to members of the Accili laboratory for insightful data discussions and for 
making the Accili lab a wonderful environment to make friends and perform excellent 
research: Jinsook Son, Diana Kuo, Takumi Kitamoto, Michael Kraakman, Wendy 
McKimpson, Liheng Wang, Joshua Cook, Fanny Langlet, Noemie Druelle, and Emi 
Ishida. A special thanks to Ja Young Kim-Muller, Utpal Pajvani, Li Qiang, Hongxia Ren, 
and Rebecca Haeusler, alums of the Accili lab that helped mentor and guide me. I thank 
Thomas Kolar, Ana Flete-Castro, Jun B. Feranil, Lumei Xu, and Q. Xu (Columbia 
University) for outstanding technical support. I thank Travis Morgenstern and Dr. Henry 
Colecraft (Columbia University) for providing the training and equipment for calcium flux 
imaging. I thank Drs. William Blaner and Seung-Ah Lee for helping with the 
quantification of retinoic acid species. I thank Drs. Lori Sussel and Rachel Kim for help 
analyzing RNA sequencing data. I thank Dr. Delfina Larrea for assisting with Seahorse 
respirometry and Dr. Magali Mondin (U. Nice) for providing us with the islet 
immunostaining quantification macro for ImageJ. I thank Dr. Läuge Schaffer (Novo 
Nordisk) for providing us with S961 InsR antagonist. I thank Enrique Garcia (Columbia 
University) for insightful discussion. I’d also like to thank the members of my thesis 
defense committee, Drs. Remi Creusot, Dieter Egli, Ron Liem, and Jeffrey Pessin for all 




I would like to dedicate my PhD dissertation to God, my wife, Sarah Elizabeth Stone 
Fan, and my daughter, Nicola Stone Fan. To Sarah: Thank you for patiently and lovingly 
standing by my side for the past 9 years. I am so lucky to have you as my partner in life. 
Thank you for helping to create our wonderful little family and for bearing and raising 
Nico. I hope our remaining time together will be filled with as much joy and love as we 
have already experienced. To Nico: Thank you for being the most wonderful little baby 
girl I could have ever hoped for. Thank you for already being so cute, quirky, and funny 
at the age of two. You bring so much joy into our lives, and I am so excited to see what 




Diabetes arises as a consequence of combined abnormalities in insulin production and 
function 3. Although alterations in either arm of this homeostatic loop can result in full-
blown disease, in most individuals, the two abnormalities coexist. While target organs 
show an impaired response to insulin (so-called insulin resistance), β-cells of diabetics 
show a blunted and mistimed response to nutrients 4. During the natural history of the 
disease, β-cell function markedly deteriorates 5. In fact, an intrinsic susceptibility of the 
β−cell to functional exhaustion–what is commonly referred to as “β-cell failure”–sets 
apart those individuals who go on to develop diabetes from those that, at the same level 
of insulin resistance, don’t 5. Abnormalities of islet cell function in diabetes include an 
impaired insulin response to stimulus, a reduced number of β-cells, and an 
inappropriate glucagon response 6. This occurs despite the fact that reversal of 
hyperglycemia can partly restore β-cell function, even in patients with advanced disease 
7. Treatments range from preserving β-cell function by reducing the metabolic demand 
on β-cells, to increasing β-cell performance to meet the increased metabolic demand 4. 
Notwithstanding this evidence, it is unclear whether the two primary components of β-
cell failure, impaired insulin secretion and reduced β-cell mass, are mechanistically 
linked. We have shown that genetic ablation of Foxo function in β-cells impairs 
metabolic flexibility, i.e., the ability to switch from glucose to lipids as a source of acetyl-
CoA for mitochondrial oxidative phosphorylation, paving the way for β-cell 
dedifferentiation 8-11. These two processes bookend β-cell failure, but we don’t know 
what happens in between. The work described in this thesis attempts to characterize 
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the progression of β-cell failure and dedifferentiation. Central to our study is the 
transcription factor FoxO1, a critical mediator of β-cell function and identity. 
 
Foxo in insulin action and β-cell function 
Foxo 1, 3a, and 4 are three genes encoding forkhead-type transcription factors. There 
are over one hundred forkhead domain-containing genes in the human genome 12, but 
there are compelling differences that account for the selective involvement of the “O” 
subfamily in hormone action, a concept first discovered in C.elegans 13, 14. Unique 
among the forkhead domain-containing proteins, Foxo change their subcellular 
localization and hence their activity in response to Akt-dependent phosphorylation as 
well as NAD+-dependent acetylation 15. The latter is thought to reflect the intracellular 
ratio of reduced NAD equivalents. Thus, Foxo can be viewed as a relay of metabolic 
signals to the nucleus. The overarching physiologic role of Foxo is to enable metabolic 
flexibility, i.e., the ability to switch from glucose to lipid utilization depending on nutrient 
availability 10, 16. However, at a more granular level, this general property morphs into a 
more nuanced mode of action. Thus, in the central nervous system Foxo integrates 
energy intake with energy expenditure through its actions on neuropeptide production, 
processing, and signaling 17-19. In liver, Foxo regulates hepatic glucose and lipid 
production, and in adipocytes, free fatty acid turnover 16, 20, 21. In the vasculature, it 
regulates nitric oxide production and inflammatory responses 22-24. In addition, Foxo has 
seemingly distinct functions in tissue differentiation and lineage determination that are 
best illustrated by its role to maintain stability of insulin-producing β-cells and prevent 
their dedifferentiation during diabetes progression 9, 25.  
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Our interest in this area was driven by the observation that Foxo subcellular 
localization changes in β-cells, depending on their pathophysiologic state8, 26. In the 
“resting” β-cell, under physiological conditions, Foxo is seemingly inactive. When β-cells 
are exposed to increased glucose and/or fatty acids levels 8, 27, or to cytokines and other 
inflammatory agents 28, Foxo undergoes nuclear translocation. This is due to different 
post-translational modifications that include phosphorylation and acetylation 15, 29. The 
residence of Foxo in the nucleus leads to activation of certain pathways and inhibition of 
others. The net outcome of this response is described below. However, it’s equally 
important to note that Foxo activation is limited in time, as the deacetylated nuclear 
protein has decreased stability 30. As Foxo levels decrease, the stage is set for 
dedifferentiation through the loss of gene expression networks necessary to the 
maintenance of β-cell characteristics 31.  
 
Insulin secretion and β-cell function 
Our understanding of the regulation of β-cell function has been shaped by the 
metabolic paradigm, according to which insulin secretion responds to metabolic cues 32. 
More controversial is the role of insulin itself as a regulator of β-cell function. The 
concept that insulin controls its own secretion remains debated, but the thrust of our 
work is that FoxOs integrate insulin/hormone-dependent pathways with 
glucose/nutrient-dependent pathways 8, thus superseding the debate on whether insulin 
or glucose are to blame for abnormal β-cell function. 
There are two main phases to insulin secretion: an ATP-dependent first phase 32, 
and a second–or amplifying–phase, variously assumed to be controlled by pyruvate 
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cycling 33, NADH shuttle 34, long-chain acyl-CoAs 35, glutamate 36, or NADPH 37, 38. 
Substrate for mitochondrial oxidative phosphorylation can be derived from glucose, 
amino acids, and lipids.  
During the first phase of insulin secretion, glucose from the blood equilibrates 
across the β-cell’s plasma membrane and is phosphorylated by glucokinase. Glucose-6-
phosphate enters the glycolytic pathway to produce pyruvate, which then enters the 
mitochondria to be metabolized by the TCA cycle. Reducing equivalents produced by 
the TCA cycle then hyperpolarize the mitochondrial membrane to generate a protein 
gradient that drives ATP synthase. The ATP produced by this process is released into 
the cytosol and triggers closure of the KATP-channel, leading to depolarization of the cell 
membrane. Depolarization then triggers opening of the voltage-dependent Ca2+ 
channels, increasing cytosolic Ca2+ to promote exocytosis of stored insulin granules. 
The second phase of insulin release sustains insulin production/secretion and 
requires the action of metabolic coupling factors, many of which originate from the 
mitochondria. For example, alpha-ketoglutarate formed by the TCA cycle can be 
converted by glutamate dehydrogenase to glutamate, which enhances glucose-
stimulated insulin secretion.39 However, in the state of metabolic excess, increased 
mitochondrial metabolism is a double-edged sword: reactive oxygen species (ROS) are 
a natural by-product of respiration and can damage mitochondrial inner membrane 
components. Extreme ROS production can even trigger apoptosis.    
The balance between glucose and lipid oxidation is very important: during 
fasting, fatty acid oxidation allows β-cells to maintain a trickle of insulin secretion; after a 
meal, the rise in plasma glucose drives mitochondrial energy generation for ATP 
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production and insulin release 6. Experimental animal studies show that Foxo activation 
in the early phases of diabetes preserves the balance between glucose and lipids in the 
generation of acyl-CoA for mitochondrial oxidation. Foxo maintains the activation state 
of the Maturity Onset Diabetes of Youth (MODY) genes Hnf4, Hnf1, and Pdx1, and 
suppresses the fatty acid oxidation network supervised by nuclear receptor Pparα, to 
curtail generation of lipid-derived acyl-CoA10, 31, 40.  
This stress response aims to preserve the physiologic balance of mitochondrial 
substrate, and keeps β-cells from “overheating” 10, 40; but again, it is not unlimited. There 
is a penalty to be paid for Foxo activation: it becomes rapidly degraded, leading to its 
depletion if hyperglycemia does not resolve 10. As Foxo expression wanes, β-cells 
switch from glucose oxidation-driven energy generation to lipid oxidation-driven energy 
generation for insulin secretion, becoming “blind” to glucose. Excessive lipid oxidation 
leads to generation of toxic products, primarily ROS and peroxides, and impairs ATP 
production, calcium mobilization, and insulin secretion. Interestingly, loss of Foxo is also 
associated with increased Pparγ and triglyceride synthesis 6. We have suggested that 
this increase is compensatory in nature, and is meant to divert acyl-CoA toward lipid 
synthesis, to alleviate mitochondrial overload. The inability of the β-cell to adapt from 
lipid to glucose utilization is similar to what has been described in other tissues as 
metabolic inflexibility 41. We have proposed that this inflexibility is a key step in β-cell 
failure 10.  
What are the long-term consequences of metabolic inflexibility? Gradually β-cells 
lose, along with insulin secretion, their terminally differentiated features. This conclusion 
was arrived at using lineage-tracing studies to monitor the fate of β-cells during diabetes 
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development 9. Talchai et al. (2012) subjected insulin promoter Ins2-
Cre+:FoxO1fl/fl:Rosa26-GFP mice to various physiological stressors (multiparity, aging, 
etc.), and followed their fate. The expectation of these experiments was that, if diabetic 
β-cells died of apoptosis, they would simply disappear over time. Instead, GFP+ β-cells 
were still present, but lost their defining features (Insulin, MafA, and Pdx1 expression) 
while gaining features of endocrine progenitor/stem cells (Neurog3, L-Myc, and Oct4 
expression). Moreover, a subset of these “dedifferentiated” cells then turned into 
glucagon-producing cells, providing a potential explanation for the hyperglucagonemia 
of diabetes 9. This observation has now been reproduced 42-46, and significantly 
advanced by the demonstration that in rodents, non-human primates, and human islets 
dedifferentiation is reversible by insulin and other treatments 25, 44, 47-50. Although insulin 
treatment of humans has not been found to result in significant restoration of β-cell 
dysfunction 51, the data raise the possibility that new agents, acting on different 
mechanisms, might prevent or reverse β−cell failure. 
 
Dedifferentiation: a cellular hypothesis rooted in clinical observation 
From the studies described above, it can be concluded that as β-cells lose their identity, 
they come to resemble endocrine progenitor cells 9, 25, 42, 43. The notion that β-cells might 
become dedifferentiated during diabetes progression has parallels in the daily clinical 
reality of treating diabetic patients. Beginning in the 1980’s, with the advent of glucose 
clamp techniques, the idea that type 2 diabetes could be subsumed under the paradigm 
of insulin resistance became commonplace. And certainly treating insulin resistance is a 
large unmet medical need 52. But prior to that, diabetes treatment was primarily viewed 
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as addressing the need to improve insulin secretion. Astute clinicians knew that insulin 
secretion becomes worse with each passing year, and early clinical studies showed the 
benefits of β-cell “rest” 7, 53, 54. Beginning with the UKDPS 55, these findings became 
settled law, jumpstarting a search for treatments that would “protect” the β-cells and 
“modify” the course of the disease. Thus, the concept of dedifferentiation provides an 
underpinning for the reversibility of β-cell failure in the early phases of diabetes, and at 
the same time an explanation for the slow decline of β-cell function. 
An important step in the process of determining the role of β-cell dedifferentiation 
was to test the human relevance of the mouse observations. While one cannot easily 
assess cellular plasticity of the endocrine pancreas in living humans, it’s however 
possible to use animal studies to formulate testable hypotheses on the expected 
features of dedifferentiated human β-cells 56, 57. With this goal in mind, our lab undertook 
a survey of human diabetic pancreata from organ donors to assess if β-cells become 
dedifferentiated. The assumptions were that dedifferentiated β-cells would no longer 
contain insulin, or other pancreatic hormones, to exclude cells arising from converted β-
cells. However, dedifferentiated cells would retain endocrine as well as progenitor cell 
features that could be detected by immunohistochemical techniques 9. Under these 
assumptions, Cinti et al. were able to confirm the prediction that β-cells become 
dedifferentiated in patients with type 2 diabetes. They found that all features of murine 
dedifferentiation occur in the human islets: ~40% of β-cells were dedifferentiated 
according to these criteria, and displayed patterns of transcription factor expression 
reminiscent of murine islets, with decreased Foxo1, Nkx6.1, and MafA. In addition, 4% 
of β-cells were degranulated, as assessed by electron microscopy.  
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Relevant to this issue is whether dedifferentiating β-cells do indeed have 
progenitor cell-like features. To address this question it’s necessary to first discover 
biomarkers that can be used to isolate and characterize “failing” β cells. In Chapter I, we 
report the discovery of an isoform of the enzyme aldehyde dehydrogenase (ALDH1A3) 
as a biomarker of dysfunctional β cells. We isolated and characterized ALDH1A3-
expressing islet cells, and compared their gene expression profiles in normal and 
diabetic mice. The data indicate that two reciprocal processes unfold in failing β cells: a 
decrease of mitochondrial function with (likely compensatory) RICTOR activation, 
associated with activation of progenitor cell-like features. We identify a narrow set of 
candidate genes that may affect the transition from a healthy to a dysfunctional β cell. 
The significance of this work consists in the discovery of a biomarker of β cell 
dysfunction that can also be used to isolate failing cells; and in the identification of a 




MATERIALS AND METHODS 
We performed genotyping as described.58, 59 Mice were maintained on a mixed 129J-
C57BL/6 background. We derived control genotypes from the same litters. Owing to the 
complexity of genotyping the 6 mutant alleles (five Foxo alleles and Rip-cre), we used 
different combinations of Foxo1, 3 and 4 floxed mice without Rip-cre transgene or Rip-
cre mice without Foxo floxed alleles 60. Sample size calculations were based on the 
variance observed in prior experiments 10, 31. These mice were indistinguishable from 
mixed 129J-C57BL/6 mice in all metabolic tests. All mice were fed normal chow and 
maintained on a 12–hour light–dark cycle (lights on at 7 AM). The Columbia University 
Institutional Animal Care and Utilization Committee approved all experiments. 
 
Cell lines. We used the mouse insulinoma cell line MIN6, obtained from ATCC, and 
previously characterized for its ability to secrete insulin 8. 
 
RNA profiling. We used GeneChip Mouse Exon arrays (Affymetrix) and performed 
data analysis with Partek Genomics Suite (Partek, Inc.) and Ingenuity Pathway Analysis 
(Ingenuity Systems, Inc.). For the analyses shown in this study, we used a threshold of 
p < 0.05 and >1.3-fold change (n = 4 WT, 3 KO per group). Each array was performed 
with pooled islets from 3 mice per genotype 10. Data have been deposited as in the 
GEO database as GSE78966. 
 
Fluorescence-Activated Cell Sorting. We isolated islets by collagenase digestion 
from 6-month-old Rip-cre Foxo1,3a,4lox/lox;RFP (ROSA-Tomato) and Rip-cre 
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Foxo1,3a,4+/+;RFP mice (10-20 animals per genotype) as described 10. We incubated 
cells with the fluorescent ALDH substrate BODIPY™-aminoacetaldehyde (aldefluor) for 
1hr prior to flow cytometry. Thereafter, cells were applied to a BD Influx sorter and 
analyzed with a BD LSRII instrument. We gated cells for RFP (red) and aldefluor 
(green) fluorescence, and sorted three sub-populations: RFP–ALDH– (non-β cells), 
RFP+ALDH– (β cells), and RFP+ALDH+ (ALDH-positive β cells).  
 
Immunoblot and immunohistochemistry. We performed immunoblotting and 
immunohistochemistry as previously described9. We used the following antibodies: 
rabbit primary antibodies to FoxO1 (Santa Cruz, Cell Signaling), somatostatin (DAKO), 
Aldh1a3 (Novus), Neurog3 (Beta Cell Biology Consortium), and MafA (Bethyl); guinea 
pig primary antibodies to insulin and glucagon (DAKO), and Pdx1 (Millipore); sheep 
primary antibodies to Somatostatin (Novus); goat primary antibodies to Pancreatic 
Polypeptide (Novus and Abcam), Somatostatin (Santa Cruz), Nkx6.1 (Santa Cruz), and 
L-Myc (R&D) ; and mouse primary antibodies to Aldh1a3 (LSBio) and Glucagon (Sigma) 
58.   
 
Mitochondrial function. We used the XF24-3 respirometer (Seahorse Bioscience) with 
24-well plates. We used the F1F0 ATP synthase inhibitor oligomycin to assess 
uncoupling, FCCP to estimate maximum respiration, and rotenone to measure non-
mitochondrial respiration 61.  
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RNA measurements. We used standard techniques for mRNA isolation and SYBR 
green quantitative PCR. PCR primer sequences have been published 9. Data have 
been deposited as GEO (number pending). 
 
Statistical analyses and general methods. Sample sizes were estimated from 
expected effect size based on previous experiments. No randomization or blinding was 
used. We present data as means ± SEM. We used two-tailed Student’s t-test, one-way 
ANOVA, or two-way ANOVA for data analysis, and the customary threshold of p <0.05 




Elevated ALDH1A3 is a common feature of diabetic β cells. We reasoned that 
critical changes in gene expression during β cell failure would be shared across multiple 
models of diabetes. We used two permutations of a genetic approach involving triple 
Foxo knockouts (Foxo1, 3a, and 4) at two distinct developmental stages: (i) in 
pancreatic precursors (generated using Pdx1-cre-mediated gene knockout) 11; (ii) in 
terminally differentiated β-cells (generated using RIP-cre) 9. The triple Foxo knockout 
faithfully replicates human MODY, a genetic form of diabetes caused by an intrinsic β-
cell abnormality 62. When we compared transcriptomes of islets from these models, a 
swath of genes was uniformly affected across the board. Among them was aldehyde 
dehydrogenase isoform 1A3 (ALDH1A3), expression of which increased 3 to 6-fold with 
robust adjusted p values (Table 1). We tested the expression of ALDH1A3 in other 
models of diabetes including aging, diet-induced, and db/db mutants, and found it to be 
increased too (Fig. 1a). We sought independent confirmation of this observation in the 
literature, and found that similar increases of ALDH1A3 had been observed in diabetic 
Nkx6.1 (Ref 43) and MafA knockout mice 63, as well as in a cross of diabetes-sensitive 
vs. resistant mice 64. ALDH1A3 is notably absent from normal β cells 65. In a recent 
study inspired by these findings, we found that ALDH1A3 is also elevated in islets from 
patients with type 2 diabetes 66. 
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Table 1. Comparison of the top 10 transcripts in two models of Foxo knockout β 
cells 
β cell-specific triple FoxO knockout (Rip-cre) Pan-pancreatic triple FoxO knockout (Pdx-cre) 
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9 
List of the 10 top overexpressed genes from microarray analysis of β cells isolated from β cell-
specific and pan-pancreatic Foxo triple Foxo knockouts compared to their relevant wild-type 
controls. 
 
ALDH1A3 had two attractive features: ALDH1 activity marks human cancer 
progenitor cells 67-70, and ALDH1A3 has been recognized as the isoform conveying 
increased ALDH1 activity in lung, ovary, breast, head and neck cancer, and melanoma 
71-73. This fits with the notion that dedifferentiating β cells have progenitor-like features 
25, 43, 74. Moreover, ALDH-expressing cells can be readily isolated using live cell assays 
75. ALDH1A3 is one of 20 murine genes encoding NAD(P)+-dependent enzymes that 
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catalyze aldehyde oxidation. ALDHs also have additional catalytic (e.g., esterase and 
reductase) and non-catalytic activities. ALDH1A3 is also known as retinaldehyde 
dehydrogenase (RALDH3) owing to its ability to synthesize retinoic acid (RA) from 
retinal. 
The increase was specific to ALDH1A3, as other isoforms showed little if any 
change (Fig. 1a and data not shown). Measurements of all-trans-RA and 9-cis-RA 
production in islets confirmed a correlation between ALDH1A3 levels and RA 
generation, indicating that the enzyme is catalytically active (Fig. 1b-c). We localized 
ALDH1A3 in islets using immunohistochemistry. ALDH1A3-positive cells were rare in 
normal islets (Fig. 2a). We studied a classic model of diabetes secondary to extreme 
obesity, db/db mice, as well as mice that develop diabetes as a consequence of 
extreme peripheral insulin resistance, brought about by targeted knockout of Insulin 
Receptor in muscle, fat, and brain (GIRKO) 1. Of note, the latter mice have no intrinsic β 
cell abnormalities, but develop diabetes as a result of their inability to compensate for 
insulin resistance. In both models, the number of ALDH1A3-expressing cells rose 
considerably (Fig. 2a-b). There was heterogeneity of immunohistochemical signal 
intensity among ALDH1A3-expressing cells. We empirically defined them as 
ALDH1A3low and ALDH1A3hi cells. ALDH1A3 immunoreactivity showed a reciprocal 
pattern with insulin immunoreactivity such that ALDH1A3hi cells were insulin-negative, 
while ALDH1A3low cells retained some insulin immunoreactivity (Fig. 2a-b). We didn’t 
detect strongly insulin-immunoreactive cells that were also ALDH1A3-positive, nor did 
we detect any other endocrine cell type that co-localized with ALDH1A3 in mouse islets 
(Fig. 2b). These data show that ALDH1A3-expressing cells are heterogeneous and are 
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comprised of insulin-producing cells as well as hormone-negative cells that can 
potentially represent a progenitor-like population. 
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Chapter I, Figure 2
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Chapter I, Figure 2 Continued 
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Chapter I, Figure 2 Continued 
 
We tested the expression of various β cell markers in ALDH1A3-positive cells. 
They had weak MafA immunoreactivity (Fig. 2c), but retained Pdx1 immunoreactivity 
(Fig. 2d). We examined Nkx6.1 expression by staining adjacent sections with insulin 
and Nkx6.1 or ALDH1A3 and Nkx6.1 and found that Nkx6.1 was generally reduced (Fig. 
2e, left and middle panels). We then performed co-staining with ALDH1A3 and Nkx6.1 
antibodies on the same section, and found that Nkx6.1 was absent in a subset of ~10% 
of ALDH1A3-positive cells (Fig. 2e, right panels, white arrows). We also examined two 
progenitor cell markers, L-myc and Neurogenin3. Consistent with previous results, we 
found that L-myc expression increased in Foxo knockout islets and that ALDH1A3-
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positive cells were L-myc-positive (Fig. 2f). Moreover, there was a subset of ALDH1A3-
positive/Neurog3+ cells (Fig. 2g, white arrows). These data provide 
immunohistochemical evidence that ALDH1A3 marks a heterogeneous cell population, 
with features of incipient β cell failure (reduced insulin), and including a subset of 
dedifferentiating (low MafA or Nkx6.1) or dedifferentiated cells (L-myc and Neurog3-
expressing) 9, 25, 43.  
 
ALDH1A3 overexpression does not impair insulin secretion. As Foxo1 loss-of-
function is associated with increased ALDH1A3 levels, we asked whether Foxo1 
regulates ALDH1A3 in MIN6 insulinoma cells. We transfected wild-type and two 
different mutant Foxo1 constructs to investigate this point. The first mutant is a 
dominant-negative that binds to DNA but lacks the transactivation domain, preventing 
binding of RNA polymerase, hence transcription. When over-expressed, it outcompetes 
endogenous Foxo (1, 3a, and 4) and effectively mimics the effect of a knockout 76. The 
second mutant, DNA-binding deficient (DBD), doesn’t bind to DNA, and fails to activate 
Foxo targets for which DNA binding is required 2. Inhibition of Foxo1 by the dominant-
negative mutant resulted in a ~ 30-fold increase in Aldh1a3 mRNA, while the DBD 
mutant Foxo1 failed to activate Aldh1a3 expression (Fig. 3a). This experiment shows 
that Foxo1 inhibits Aldh1a3 independently of DNA binding, likely acting as a co-
repressor 2, 77. These data are consistent with the possibility that activation of ALDH1A3 
expression is an early correlate of reduced Foxo1 function.  
Reduced RA signaling in islets has been linked to defective insulin secretion 78. 
To test whether elevated ALDH1A3 activity affects β cell function, we overexpressed 
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ALDH1A3 in MIN6 cells using either transient transduction with adenovirus (Fig. 3b) or 
the derivation of stably transfected clones, and then measured expression of genes that 
are important for β cell function or glucose-stimulated insulin secretion. In either case, 
we found no defects in gene expression (Fig. 3c) or insulin secretion (Fig. 3d). 
Moreover, we transduced islets of wild-type C57Bl/6J mice with ALDH1A3 adenovirus 
and found a small, but statistically significant increase of glucose-induced insulin 
secretion (Fig. 3e). ALDH1A3 activity can be inhibited by the irreversible inhibitor N,N-
diethylaminobenzaldehyde (DEAB) 75. We performed insulin secretion experiments in 
MIN6 cells overexpressing ALDH1A3, as well as in db/db mice with endogenously 
elevated ALDH1A3, in the presence of DEAB. But we didn’t detect an effect of this 
compound to change insulin secretion (Fig. 3f). Finally, we measured oxygen 
consumption in MIN6 cells overexpressing ALDH1A3 as a surrogate of mitochondrial 
function, and found a modest decrease (Fig. 3g). However, in light of the fact that insulin 
secretion was normal (in MIN6) or slightly elevated (in primary islets), we suppose that 
this slight oxidative defect is unlikely to result in a functional change. These data 
showing that acute gain-of-function of ALDH1A3 doesn’t compromise β cell function 
suggest that ALDH1A3 is a marker, rather than a cause of β cell dysfunction.  
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Chapter I, Figure 4 Continued 
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Isolation and functional characterization of ALDH1A3-expressing islet cells. We 
used a vital assay of ALDH activity to isolate ALDH1A3-expressing cells from mouse 
islets (Fig. 4a). The cell-permeable fluorescent ALDH substrate BODIPY™-
aminoacetaldehyde (aldefluor) is metabolized to the non-releasable derivative 
BODIPY™-aminoacetate (BAA), thus permanently labeling ALDH-expressing cells. We 
used RFP to label β (or former β) cells by cre-mediated recombination 9. Thereafter, we 
incubated cells with aldefluor, and selected for RFP (red) and aldefluor (green) 
fluorescence, yielding ALDH– and ALDH+ β cells. The latter should include 
dysfunctional/dedifferentiating β cells. In wild-type mice, we obtained three sub-
populations: RFP–ALDH– (non-β cells), RFP+ALDH– (healthy β cells), and RFP+ALDH+ 
(dysfunctional β cells) (Fig. 4b). The latter represented less than 1% of total cells in 
normal islets. In separate experiments, we isolated RFP+ALDH+ cells from animals with 
β cell-specific (RIP-cre) triple Foxo1 knockouts 10. As predicted, the RFP+ALDH+ sub-
population increased about 7-fold in this model (Fig. 4c-d).  
We performed a preliminary characterization of ALDH– and ALDH+ cells by 
measuring insulin secretion and gene expression. The predicted outcome of these 
experiments was that ALDH+ cells would be: (i) enriched in ALDH1A3; (ii) impaired in 
their ability to secrete insulin; (iii) depleted of markers of functional β cells, including 
Foxo1 10. All predictions were borne out by the data. In glucose-stimulated insulin 
release experiments using ALDH– vs. ALDH+ cells, we found that only the former 
responded to glucose, providing critical evidence for a functional impairment of ALDH+ 
cells (Fig. 4e). Aldh1a3 mRNA was restricted to the RFP+ALDH+ population in both wild-
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type and triple Foxo knockout mice (Fig. 4f). Foxo1 was reduced by ~70% in ALDH+ 
cells from wild-type mice (Fig. 4g). Glucokinase was nearly equally represented in all 
fractions, but was decreased in ALDH+ cells of triple Foxo knockouts (Fig. 4h), similar to 
previously reported single knockouts 9. Insulin2 and Nkx6.1 expression were greatly 
enriched in the RFP+ population, while glucagon and somatostatin were enriched in the 
RFP– population (Fig. 4i-l), providing another key element to support the identity of 
these cells. Foxo1 target MafA was enriched in the RFP+ALDH– population and 
drastically reduced in RFP+ALDH+ cells. These data are consistent with the notion that 
ALDH+ cells are β cells that have lost key functional features (Fig. 4m). Finally, Glut2 
expression was restricted to RFP+ cells, regardless of their ALDH status, and was 
significantly decreased in Foxo knockouts, consistent with prior findings (Fig. 4n) 9. 
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Chapter I, Figure 5
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Transcriptome of ALDH+ cells and progression of β cell failure. We carried out 
RNA sequencing analyses comparing ALDH+ with ALDH– β cells (RFP+), as well as 
other islet cell types (RFP–) in wild-type mice. Moreover, we compared wild-type ALDH+ 
cells with triple Foxo-deficient ALDH+ cells generated by knocking out Foxo in mature β-
cells 10. As a quality control, we interrogated expression of all 20 Aldh transcripts, and 
found that only Aldh1a3 showed differential expression in the ALDH+ population (Fig. 
5a). Moreover, in all comparisons between ALDH+ and ALDH– cells, Aldh1a3 was 
among the top differentially expressed genes (Table 2). This finding confirms the 
specificity and robustness of the enrichment technique. 
First, we analyzed differences in the levels of individual transcripts expressed in 
ALDH+ vs. ALDH– cells of wild-type mice. Using p<0.05 adjusted for multiple 
comparisons as threshold, we found 671 differentially expressed transcripts. A curated 
sub-list is shown in Table 2 and a complete list in Supplemental Table 1. The transcripts 
fell into three broad categories: terminal differentiation of β cells, mitochondrial oxidative 
phosphorylation, and ribosomal subunits. ALDH+ cells were depleted of transcripts 
encoding insulin, IAPP, Cpe, transthyretin, as well as other pancreatic hormones 
commonly found at low levels in β cells 79, and were enriched in transcripts encoding 
markers of uncommitted endocrine progenitors, such as Pax6, Rfx6, Rfx7, Mlxipl, as 
well as transcription factors associated with progenitor cell differentiation, such as Ncor, 
Hic1, and Bach2. Next, there was a striking decrease of selected mitochondrial 
components: ~30% of complex I NADH dehydrogenase subunits (13 of 41), complex IV 
cytochrome C oxidase subunits (8 of 25), and complex V F1 ATP synthase subunits (15 
of 54) were substantially decreased. In addition, ~30% of genes (28 of 92) encoding 
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ribosomal 40S and 60S subunits were coordinately decreased (Table 2 and 
Supplemental Table 1). Interestingly, 6 of the top 12 differentially expressed transcripts 
were long noncoding RNAs that have been associated with β cell dysfunction: Malat1, 
Neat1, Meg3, Peg3, Sngh11, and Kcnq1ot1 80, 81. These highly abundant transcripts 
increased from 2.5 to 12-fold in ALDH+ cells (Table 2). 
 
Table 2. Curated list of differentially expressed transcripts in wild-type ALDH– vs. 
ALDH+ cells 
Gene ALDH– ALDH+ Fold change 
Log2 Fold 
Change P  P adjusted Function 
Aldh1a3 43.89 1016.56 23.16 4.53 6.71E-24 1.13E-20 Biomarker 
Ins1 2590036.28 1940536.28 0.75 -0.42 0.000930546 0.027522748 Hormone production 
Gcg 8148.96 3014.79 0.37 -1.43 5.72E-05 0.00332584  
Ppy 2650.81 496.46 0.19 -2.42 1.23E-21 1.55E-18  
Pyy 5362.39 860.08 0.16 -2.64 3.61E-37 1.10E-33  
Gipr 158.22 527.98 3.34 1.74 0.000249629 0.010434218  
Malat1 28383.66 317323.72 11.18 3.48 3.39E-60 5.14E-56 LncRNA 
Meg3 1394.28 14866.79 10.66 3.41 3.32E-52 2.52E-48  
Neat1 1293.07 8685.24 6.72 2.75 1.34E-30 2.91E-27  
Peg3 10847.19 26432.85 2.44 1.29 6.41E-22 9.35E-19  
Snhg11 142.49 2397.86 16.82 4.07 4.52E-43 1.71E-39  
Kcnq1ot1 775.61 5750.38 7.41 2.89 1.90E-30 3.61E-27 
 Bach2 16.18 238.66 14.75 3.88 5.61E-06 0.000512996 Cellular differentiation 
Mlxipl 1521.05 6819.86 4.48 2.16 1.35E-33 3.42E-30  
Hic2 58.41 260.05 4.45 2.15 0.001977283 0.046291597  
Ncor1 3821.50 6625.10 1.73 0.79 1.41E-06 0.000162812  
Pax6 2560.43 4087.64 1.60 0.67 0.000270125 0.010988238  
Rfx6 1409.36 2881.95 2.04 1.03 1.46E-06 0.000166394  
Rfx7 916.06 1825.98 1.99 1.00 8.29E-05 0.004444825  
Sall1 94.36 0.00 0.00 INF 8.19E-05 0.004414367  
Atp1a1 9889.83 6215.32 0.63 -0.67 1.55E-05 0.001206084 Complex V 
Atp1b3 1251.14 575.26 0.46 -1.12 0.000162268 0.007646262  
Atp5a1 6810.79 3792.69 0.56 -0.84 0.000857639 0.025870698  
Atp5c1 2636.63 1433.09 0.54 -0.88 0.000205123 0.009162496  
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Atp5e 1589.03 326.47 0.21 -2.28 4.43E-14 3.05E-11  
Atp5g1 1096.95 567.38 0.52 -0.95 0.00203175 0.047209409  
Atp5g3 1859.61 960.27 0.52 -0.95 0.001441708 0.037046485  
Atp5j 1475.00 831.94 0.56 -0.83 0.002127738 0.048474728  
Atp5o 865.54 342.23 0.40 -1.34 0.000171152 0.007869345  
Atp6v0d1 2455.93 1463.49 0.60 -0.75 0.00077602 0.024052844  
Atp6v0e 1202.47 538.11 0.45 -1.16 0.000130094 0.006429695  
Atp6v1b2 3943.01 2468.79 0.63 -0.68 0.000378227 0.014275718  
Atp6v1c1 1737.43 1004.18 0.58 -0.79 0.001718365 0.042052834  
Atp6v1e1 1431.67 598.90 0.42 -1.26 1.06E-05 0.000867355  
Atp6v1f 634.28 162.11 0.26 -1.97 0.000947641 0.027859186  
Cox17 750.09 184.62 0.25 -2.02 6.45E-07 8.30E-05 Complex IV 
Cox4i1 1686.10 526.86 0.31 -1.68 1.82E-09 4.67E-07  
Cox6a1 1830.11 875.84 0.48 -1.06 2.98E-05 0.001962504  
Cox6b1 1089.61 258.92 0.24 -2.07 6.69E-05 0.003759072  
Cox6c 884.60 370.38 0.42 -1.26 0.000315848 0.012447694  
Cox7a2 1190.38 303.96 0.26 -1.97 1.45E-07 2.10E-05  
Cox7b 1696.32 749.76 0.44 -1.18 8.68E-06 0.000739806  
Cox8a 1783.45 988.42 0.55 -0.85 0.000706031 0.022364515  
Cyp27b1 3.75 233.03 62.20 5.96 5.50E-09 1.27E-06  
Ndufa11 966.85 229.66 0.24 -2.07 1.31E-08 2.62E-06 Complex I 
Ndufa13 817.24 334.35 0.41 -1.29 0.00038447 0.014368374  
Ndufa2 602.15 164.36 0.27 -1.87 2.40E-05 0.001645658  
Ndufa5 230.83 20.26 0.09 -3.51 2.27E-05 0.001566944  
Ndufb10 742.86 319.72 0.43 -1.22 0.001246519 0.033123357  
Ndufb11 944.43 369.25 0.39 -1.35 8.00E-05 0.004381781  
Ndufb2 416.34 126.09 0.30 -1.72 0.000918555 0.027274428  
Ndufb3 396.07 126.09 0.32 -1.65 0.001797277 0.043148871  
Ndufb8 813.88 219.52 0.27 -1.89 0.000579175 0.019313885  
Ndufb9 1211.79 431.17 0.36 -1.49 1.97E-06 0.000210659  
Ndufc2 1486.70 614.67 0.41 -1.27 5.86E-06 0.000532564  
Ndufs6 376.69 64.17 0.17 -2.55 1.64E-05 0.001253071  
Ndufv3 828.81 390.64 0.47 -1.09 0.002157213 0.048852832  
Ndor1 209.90 782.40 3.73 1.90 2.66E-06 0.000269397  
Rpl13a 1619.13 636.05 0.39 -1.35 9.07E-07 0.000111832 Ribosomal subunits 
Rpl14 1448.69 471.69 0.33 -1.62 4.09E-08 6.95E-06  
Rpl22 1352.84 681.09 0.50 -0.99 0.000488305 0.017393076  
Rpl22l1 742.74 272.43 0.37 -1.45 0.000170912 0.007869345  
Rpl29 977.46 466.06 0.48 -1.07 0.001104889 0.03059486  
Rpl32 3663.74 1316.01 0.36 -1.48 1.61E-12 7.87E-10  
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Rpl36al 1651.97 891.60 0.54 -0.89 0.000614025 0.020206063  
Rpl38 301.12 47.28 0.16 -2.67 6.52E-05 0.003690809  
Rpl41 9232.17 3217.42 0.35 -1.52 6.15E-09 1.37E-06  
Rpl8 3049.55 1108.87 0.36 -1.46 4.04E-11 1.57E-08  
Rplp0 1081.18 529.11 0.49 -1.03 0.000975463 0.028353845  
Rplp1 2091.32 552.75 0.26 -1.92 2.97E-13 1.73E-10  
Rps11 1754.68 761.01 0.43 -1.21 4.37E-06 0.000416959  
Rps14 1438.54 333.23 0.23 -2.11 3.75E-05 0.002361914  
Rps15 2313.78 865.71 0.37 -1.42 4.51E-09 1.07E-06  
Rps15a 1076.58 395.14 0.37 -1.45 9.87E-06 0.000831648  
Rps17 704.56 307.33 0.44 -1.20 0.001832148 0.043778235  
Rps20 1126.82 388.39 0.34 -1.54 2.17E-06 0.000225538  
Rps21 1023.31 452.56 0.44 -1.18 0.000289137 0.011636817  
Rps24 1994.06 717.11 0.36 -1.48 9.24E-09 1.95E-06  
Rps25 1320.93 670.95 0.51 -0.98 0.000635685 0.020609513  
Rps27l 936.36 274.69 0.29 -1.77 8.32E-07 0.000104333  
Rps28 447.27 119.33 0.27 -1.91 0.000196341 0.008813862  
Rps3 3520.68 1400.45 0.40 -1.33 2.01E-10 6.61E-08  
Rps4x 2240.30 701.35 0.31 -1.68 2.39E-11 9.56E-09  
Rps5 4075.84 1368.92 0.34 -1.57 1.36E-14 9.85E-12  
Rps6kb2 137.19 466.06 3.40 1.76 0.000448689 0.016209421  
Rps9 1981.66 722.74 0.36 -1.46 1.44E-08 2.84E-06  
 
This table lists a subset of genes differentially expressed between ALDH– and ALDH+ cells, 
arranged by functional category.  
 
We next used the “upstream regulator analysis” function of the Ingenuity Analysis 
program to identify contributors to the phenotype of ALDH+ cells based on coordinated 
changes affecting their downstream effectors and regardless of whether the regulator’s 
own expression levels changed. Z-scores were used to predict activation or inhibition of 
individual networks 10. This analysis confirmed that the main differences between 
ALDH+ and ALDH– cells could be subsumed under mitochondrial oxidative 
phosphorylation and revealed a strong potential activation of the RICTOR branch of 
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mTOR signaling. Importantly, the same top five pathways were altered in ALDH+ cells 
isolated from wild-type and triple Foxo knockout mice, confirming that most differences 
between wild-type and Foxo-deficient ALDH+ cells are of a quantitative, rather than 
qualitative nature (Table 3). 
 
Table 3. Pathway analysis of RNA sequencing in wild-type and Foxo knockout β 
cells 
Wild-type ALDH– vs. ALDH+ p 
Oxidative Phosphorylation 8.58E-27 
Mitochondrial Dysfunction 1.02E-23 
EIF2 Signaling  1.31E-15 
mTOR signaling    1.81E-10 
Regulation of eIF4 and p70S6K Signaling  7.17E-10 
 
Foxo knockout ALDH– vs. ALDH+ 
 
EIF2 Signaling  6.88E-08 
Oxidative Phosphorylation 1.29E-07 
Mitochondrial Dysfunction  2.14E-06 
Regulation of eIF4 and p70S6K Signaling  1.05E-04 
mTOR signaling 3.78E-04 
  
The table summarizes top pathways from transcriptome analysis of ALDH– vs. ALDH+ cells.  
 
Transcription factor network analyses indicated that ALDH+ cells have 
stem/progenitor cell properties, based on the combination of activated GATA, Wnt, 
Nanog, and Neurog3 82 and decreased Foxo and Notch signaling (Table 4 and 
Supplemental Table 2). Of note was also the marked inhibition of two master regulators 
of mitochondrial biogenesis and function, NFE2L2 and NRF1, consistent with the data in 
Table 2. NRF1 activates expression of EIF2A1 as well as genes required for 
mitochondrial biogenesis, function, and mitochondrial DNA transcription 83. The 
inhibition of NRF1 is consistent with the decrease of Tfam and Eif2 signaling in ALDH+ 
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cells (Supplemental Table 2). NFE2L2 is involved in NRF2-mediated oxidative stress 
and unfolded protein response 84.  
 




GATA4 2.607 1.00 x10-1 
GATA6 2.111 1.00 x10-1 
NKX6.1 1.969 2.68 x10-2 
PDX1 1.575 2.11 x10-6 
NANOG 1.508 1.62 x10-2 
GLIS3 1.384 8.57 x10-4 
CTNNB1 1.366 2.66 x10-2 
HNF1A 1.028 1.39 x10-2 
NEUROD1 0.741 4.70 x10-4 
NEUROG3 0.791 1.38 x10-4 
RBPJ –2.130  1.00 x10-1 
FOXO1 –1.811 4.91 x10-3 
FOXO3 –1.400 2.92 x10-3 
FOXO4 –0.640 1.87 x10-2 
HNF4A –1.212 1.39 x10-2 
NKX2.2 –1.000 2.65 x10-4 
Z-score analysis of transcriptional networks involved in pancreas development in ALDH+ cells. 
 
This analysis also indicated activation of RICTOR (mTORC2) signaling. RICTOR 
promotes β cell growth and insulin secretion85. However, other features of ALDH+ cells 
suggest that the activation of RICTOR is compensatory in nature. For example, ATF4-
mediated signaling is inhibited, thus leading to decreased unfolded protein response 
and apoptotic signaling in response to endoplasmic reticulum stress. There are 
impairments in insulin and IGF1 receptor signaling, as well as inhibition of the 
transcriptional network overseen by nuclear receptor NR4A3, which is required for β cell 
growth (Supplemental Table 2) 86. The decrease in insulin/IGF receptor signaling is 
consistent with the homeostatic role of Foxo in these pathways, such that low Foxo 
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would be expected to result in impaired insulin/IGF receptor signaling 23. In addition, the 
mild activation of Src and EGF receptor signaling observed in ALDH+ cells suggests that 
cells are shifting from a fully differentiated phenotype maintained through insulin 
receptor/Foxo signaling, to a less differentiated phenotype dependent on oncogene 
signaling with features of progenitor cells (Supplemental Table 2).  
Two other features of ALDH+ cells deserve mention: the decrease in estrogen 
receptor signaling, and activation of inflammation pathways, including NFKB1, MYD88, 
TICAM1, IFRD1, TLR7, CXCL12, and IL6 (Supplemental Table 2).  
 
Comparing wild-type and Foxo knockout ALDH+ cells. Next, we compared ALDH+ 
cells from wild-type and triple Foxo-deficient mice. The rationale was threefold: first, 
although ALDH1A3 expression is a marker of reduced Foxo activity, Foxo is not absent 
in the majority of these cells, and complete Foxo ablation may exacerbate their 
phenotype; second, it may reduce heterogeneity of ALDH+ cells; and third, because 
Foxo-deficient mice develop a MODY-like form of diabetes, this comparison might 
reveal qualitative differences between ALDH+ cells isolated from euglycemic vs. diabetic 
animals. One can hypothesize that complete genetic ablation of Foxo mimics the final 
stages in the progression of the fate of ALDH+ cells and that, by analyzing differences 
between wild-type and Foxo-deficient ALDH+ cells, it’s possible to identify genes that 
mark the mechanistic progression to an advanced phase of cellular failure, or a tipping 
point toward dedifferentiation (Fig. 5b).  
When we compared transcriptomes of wild-type vs. triple Foxo knockout ALDH+ 
cells, we found few differentially expressed genes, as predicted (Tables 5 and 6). The 
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dearth of differences between wild-type and Foxo-deficient ALDH+ cells is wholly 
consistent with the concept that in diabetes there is a “spontaneous” loss of Foxo 8-10, 
and that Foxo normally restrains ALDH1A3 expression (Fig. 3). Nonetheless, these 
genes indicated potential pathogenic processes unfolding in failing β cells. A striking 
aspect of the gene expression profile of Foxo-deficient ALDH+ cells is the decrease in 
Cyb5r3. This gene encodes cytochrome b5 reductase isoform 3, one of four b5 
reductase subunits (r1 through 4). Its expression is regulated by Foxo and Nrf, 
consistent with our findings 87. Cyb5r3 has a membrane-bound and a soluble form, the 
latter of which is restricted to erythrocytes. It utilizes NADH and NADPH to synthesize 
long-chain fatty acids, and it’s also required for mitochondrial complex III function. 
Cyb5r3-deficient cells show decreased NAD+/NADH ratios, mitochondrial respiration 
rate, ATP production, and mitochondrial electron transport 87. Notably, knockout of the 
related isoform Cyb5r4 causes early-onset β cell failure in mice independent of 
peripheral insulin sensitivity 88.  
Other interesting genes that are specifically altered in Foxo-deficient ALDH+ cells 
include: Elovl6, Ndor, and Cyp27b1. Elovl6 is a long chain fatty acid elongase that plays 
an important role in liver 89. In β cells, its expression pattern mirrors Cyb5r3, and can 
potentially act in concert with the latter to synthesize long-chain FA. Similarly, the 
NAPDH-dependent oxidoreductase Ndor, whose expression levels track closely those 
of Foxo in ALDH+ cells, could also be involved in mitochondrial processes related to 
Cyb5r3. Cyp27b1 is required for the synthesis of 1,25-OH vitamin D3, and there is some 
evidence that it participates in β cell dysfunction in diabetes 90. Finally, there were two 
transcripts that showed opposite changes in wild-type vs. Foxo-deficient ALDH+ cells: 
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the lncRNA Peg3, a parentally imprinted transcript whose methylation correlates with 
human islet function 91, and Bach2, a transcription factor that has been implicated in 
type 1 diabetes susceptibility 92, 93, as well as β cell stress 94 (Table 6).  
 
Table 5. Top 25 differentially expressed transcripts in ALDH+ cells from wild-type 







Change P Adjusted P 
Foxo1 1005.01 131.37 0.13 -2.94 2.23E-11 3.47E-07 
Cyb5r3 5076.01 1742.73 0.34 -1.54 8.29E-09 6.46E-05 
Cyp27b1 206.80 4.83 0.02 -5.42 5.10E-07 0.002649712 
Elovl7 384.62 38.27 0.10 -3.33 1.46E-06 0.005684329 
Hip1r 1463.56 467.44 0.32 -1.65 2.98E-06 0.009288892 
Bach2 211.79 11.73 0.06 -4.17 2.45E-05 0.052959279 
Ctsl 2272.77 5237.71 2.30 1.20 3.39E-05 0.052959279 
Etl4 1573.45 590.80 0.38 -1.41 3.21E-05 0.052959279 
Muc4 3932.14 763.76 0.19 -2.36 3.32E-05 0.052959279 
Ptprt 753.26 181.42 0.24 -2.05 2.71E-05 0.052959279 
Dnahc17 112.89 1.32 0.01 -6.41 3.87E-05 0.054903167 
Spp1 3933.14 1896.47 0.48 -1.05 0.000104638 0.136037989 
Gpc6 72.93 0.00 0.00 N/A 0.000119737 0.14369393 
Cxcl13 71.93 0.00 0.00 N/A  0.000135081 0.150528447 
Prnd 93.91 1.06 0.01 -6.47 0.000149671 0.155667934 
2010015L04Rik 249.75 32.76 0.13 -2.93 0.000188906 0.173360099 
Ncam1 2471.57 1148.98 0.46 -1.11 0.000183578 0.173360099 
Jam2 437.57 97.38 0.22 -2.17 0.000207049 0.179454216 
Galntl4 316.69 53.81 0.17 -2.56 0.000328609 0.269822705 
D0H4S114 613.40 190.91 0.31 -1.68 0.000492415 0.351638321 
Hcn1 76.92 0.60 0.01 -7.01 0.000495868 0.351638321 
Nog 61.94 0.00 0.00 N/A  0.000451442 0.351638321 
Cox6b1 229.77 695.81 3.03 1.60 0.000553818 0.362501015 
Krba1 424.58 108.79 0.26 -1.96 0.000565259 0.362501015 
 
This table lists a subset of genes differentially expressed between wild-type and triple Foxo-
deficient ALDH+ cells, arranged by p-value.  
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Table 6. Overview of key differential changes in transcript profile of wild-type and 
















Category list of principal genes altered in ALDH+ cells as a function of Foxo genotype. Upward 
arrows indicate genes with increased expression, downward arrows indicate genes with 
decreased expression. Arrows in the Foxo column indicate that the change is specific to Foxo 
knockout ALDH+ cells.   
Change Gene or network Wild-type Foxo KO 
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The key finding of this work is the identification of a subpopulation of ALDH+ islet β cells. 
Based on their impaired insulin secretory properties and transcriptional signature, we 
propose that ALDH+ cells are failing β cells. They show conjoined features of the two 
cardinal processes bookending β-cell failure: mitochondrial dysfunction 10 and 
progenitor-like features 9. We propose the following model (Fig. 5b): when β cells are 
subject to increased demand for insulin production, they increase cellular metabolism 
and substrate flux through mitochondria. Foxo is activated to maintain normal oxidative 
function and prevent cellular overwork 8, 9. The tradeoff of increased Foxo function is 
increased Foxo degradation 8, leading to eventual loss of the protein. As Foxo levels 
decline, ALDH1A3 is activated; thus, elevated levels of ALDH1A3 are a harbinger of β 
cell failure. In the progression of the cellular pathology, mitochondrial complex I, IV, and 
V functions are impaired, leading to reduced ATP production, stalling of protein 
translation, and reactivation of genes that sustain a cellular progenitor program. When 
Foxo levels reach their nadir (a situation phenocopied by genetic knockout of Foxo), a 
further subset of genes becomes altered, including Cyb5r3, Elovl6, and Bach2 (Fig. 5b). 
We propose that these genes play a pathogenic role in β cell dedifferentiation. Further 
studies to test their involvement in this process are underway, with the expectation that 
they are key mediators of progression of β cell failure, and with the ultimate goal of 




Aldehyde dehydrogenase as a marker of β cell failure. The role of ALDH1A3 in β 
cell failure will have to be determined through further studies. In oncology, there is no 
consensus on whether ALDH1A3 is a marker or a pathogenic factor in cancer 
progression 69. Our data indicate that ALDH1A3 overexpression doesn’t untowardly 
affect β cell function, but these experiments don’t capture the complexity of the potential 
roles of ALDH1A3 in β cell failure. For example, ALDH1A3 could promote mitochondrial 
dysfunction–the paramount feature of ALDH+ cells–by activating RAR/RXR signaling via 
RA production. This can result in increased Pparα function, a feature of metabolically 
inflexible β cells 10. This effect may require a specific duration or additional contributors, 
and would have gone undetected in the experiments carried out so far. To address this 
and other possibilities, we are generating appropriate models of loss- and gain-of-
function. 
 
Mechanisms of cellular failure. A prominent aspect of the gene expression profile of 
ALDH+ cells is the extent of impairment of mitochondrial gene expression. In addition to 
decreased complex I, IV, and V subunit expression, ablation of Foxo also causes a 
profound decrease of Cyb5r3. The latter is likely a Foxo target 87. Cyb5r3 mutations in 
humans cause methemoglobinemia 87. The membrane-bound form localizes to 
mitochondria and endoplasmic reticulum, where it catalyzes desaturation and 
elongation of fatty acids, as well as cholesterol biosynthesis. Cyb5r3 generates reducing 
equivalents NAD+ and NADP+, and utilizes malonyl CoA and NADPH to make 18:1, 
20:1, and 18:0 fatty acids in ratios of 65:20:15. Cyb5r3-deficient cells have decreased 
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NAD+/NADH ratios, mitochondrial respiration, ATP production, and mitochondrial 
electron transport. This results in higher oxidative stress and senescence 87.  
Cyb5r3 is a striking candidate as a β cell failure gene. One can envision that in the 
context of already impaired mitochondrial complex I, IV, and V function in ALDH+ cells, 
the drop in Cyb5r3 would result in the additional loss of NADH and NADPH reductase 
activity at the level of complex III, decreasing levels of reduced cytochrome B and C. 
This may lead to a drop in NAD+ levels to the point where glycolysis is effectively stalled 
for lack of reducing equivalents. In mice, knockout of the related isoform, Cyb5r4, 
causes early-onset β cell failure independent of peripheral insulin sensitivity 88. In yeast, 
the Cyb5r3 ortholog NQR1 extends lifespan in a SIR2-dependent manner and increases 
oxidative metabolism 95. Mitochondrial Cyb5r3 activity is increased by calorie restriction 
95 (a condition in which β cells oxidize more FA) and decreased by exposure to elevated 
glucose levels 96.  
In addition to its role in complex III function, Cyb5r3 could prevent β cell failure 
through its role in fatty acid synthesis, effectively shunting away excess fatty acyl-CoA 
from mitochondria. This would be achieved in part through activation of the Pparγ 
program, an interesting feature consistent with the paradoxical increase of Pparγ 
function in metabolically inflexible β cells 10. A decrease of Cyb5r3 levels can lead to 
fatty acid accumulation in the oxidative pathway, and worsen mitochondrial stress 
through formation of peroxides or other superoxide products. In this regard, it should be 
noted that another gene specifically affected by Foxo knockout in ALDH+ cells is Elovl6, 
whose function to increase long-chain fatty acid synthesis complements that of Cyb5r3. 
While isolated knockout of Elovl6 has no apparent detrimental effect in β cells 97, it 
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remains to be seen whether this is also true in the context of the failing β cell and in the 
absence (or deficiency) of Cyb5r3. 
An additional interesting candidate emerging from the analysis of Foxo-deficient 
ALDH+ cells is Bach2. It increases in wild-type ALDH+ cells, but decreases in Foxo 
knockout ALDH+ cells (Fig. 5b). Our interpretation of these data is that Bach2 is induced 
by Foxo when the latter undergoes nuclear translocation 8, 9, and decreases as Foxo is 
cleared from β cells. A transcriptional repressor first identified as a lineage selector of B-
lymphocytes 98, Bach2 has emerged as a genetic susceptibility locus in GWAS studies 
of human type 1 diabetes 92, 93, and has been found to protect β cells from apoptosis 
and oxidative stress 94. In addition, its ability to regulate differentiation in the 
hematopoietic lineage 98 raises the question of whether it has similar effects in 
endocrine cells, a hypothesis consistent with Bach2’s ability to drive transcription from 
Maf sites, which are known to confer β cell transcriptional features 63, 99.  
 
LncRNAs in ALDH+ cells. ALDH+ cells are strikingly enriched in selected lncRNAs: 6 of 
the 12 top differentially expressed transcripts belong to this category. At least three of 
these transcripts have previously been linked to human β cell dysfunction: Malat1, 
Meg3, and Kcnq1ot1. Malat1 is encoded in an enhancer cluster associated with β cell-
specific transcription factors 100. Meg3 is part of an imprinted locus that confers 
susceptibility to type 1 diabetes 101 and includes the atypical Notch ligand Dlk1, a 
negative regulator of adipocyte differentiation, as well as another gene, Rtl1, whose 
transcripts are also among the top enriched mRNAs in ALDH+ cells (Supplemental 
Table 1) 81. Finally, Kcn1qot1 is part of an imprinted locus that includes IGF2 and the 
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Beckwith-Wiedemann locus 80 and has been linked to type 2 diabetes susceptibility 102.  
We don’t know the targets, let alone the functional consequences, of these changes in 
lncRNA profile of ALDH+ cells, but we envision them to herald epigenetic changes 
leading to dedifferentiation. 
In sum, the present work advances our understanding of β cell failure and 
provides a series of testable targets to explain mechanisms of progression from 
impaired insulin secretion to cellular dysfunction and dedifferentiation. 
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CHAPTER I SUPPLEMENTARY INFORMATION 
 
The following supplemental tables are available online: 
 
Supplemental Table 1 Complete list of differentially expressed transcripts in wild-
type ALDH– vs. ALDH+ cells. This table lists a complete set of genes differentially 
expressed between ALDH– and ALDH+ cells, arranged by p-value.  
 
Supplemental Table 2 Ingenuity analyses of differentially expressed transcripts in 
wild-type ALDH– vs. ALDH+ cells. A partial list of different Ingenuity Pathway analyses 
to identify trends in gene expression in the different islet cell types. 
 
Supplemental Table 3 List of differentially expressed transcripts in ALDH+ cells 
from wild-type and Foxo knockout mice. This table lists all genes differentially 
	 44	






A hallmark of diabetes is β-cell failure, a state in which chronically 
increased demand for insulin exceeds the β-cell’s secretory capacity and leads to 
a gradual deterioration of β-cell mass and function. This decline manifests as a 
mistimed and diminished response to nutrients and, combined with peripheral 
insulin resistance, gives rise to hyperglycemia. Although current therapies seek 
to improve β-cell performance or reduce the demand for insulin, they are 
insufficient to halt disease progression.103-105 
Recent work established β-cell dedifferentiation as a mechanism of β-cell 
dysfunction.106-112 We have proposed that dedifferentiation is the end result of altered 
mitochondrial substrate utilization, or “metabolic inflexibility”.10 The implication of this 
model is that acting on the mechanism of mitochondrial dysfunction may prevent 
dedifferentiation or even promote “re-differentiation” of β-cells as a novel form of 
therapy. However, the mechanism by which metabolic inflexibility affects mitochondrial 
function remains unclear. To address this question, we used a combination of marker 
analysis and RNA profiling to compile a list of potential effector genes of β-cell failure.113 
A strong candidate emerging from this analysis is cytochrome b5 reductase 3 (Cyb5r3).  
Cyb5r3 is unique as a candidate β-cell failure gene: it encodes a flavoprotein with 
membrane-bound and soluble forms, the latter of which is restricted to erythrocytes.114 
Mutations in this form lead to recessive congenital methemoglobinemia (Type I) while 
mutations in the membrane-bound form can cause severe neurological disease (Type 
II).115 Membrane-bound Cyb5r3 has complex functions in fatty acid desaturation, 
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cholesterol biosynthesis, antioxidant reduction, and mitochondrial electron transport 
chain (ETC) activity.114, 116 Notably, knockout of the related isoform Cyb5r4 causes 
early-onset β-cell failure in mice independent of peripheral insulin sensitivity.117 
In this study, we report that Cyb5r3 links FoxO1 signaling to β-cell mitochondrial 
ETC function, affecting the generation of reactive oxygen species, NAD/NADH ratios, 
and stimulus/secretion coupling. Consistent with the “metabolic inflexibility” hypothesis, 
these defects are exacerbated when islets are exposed to fatty acids. Mice with β-cell-
specific deletion of Cyb5r3 exhibit glucose intolerance due to impaired insulin secretion, 
a blunted response to insulin secretagogues, and decreased mitochondrial respiration. 
Moreover, Foxo1 is unable to preserve expression of key markers of β-cell 
differentiation in Cyb5r3-deficient β-cells, indicating that Cyb5r3 is required for the 
FoxO1-dependent compensatory response. These data indicate that Cyb5r3 is a key 
effector of β-cell failure, and highlight a pathway of potential therapeutic import to 
intervene on disease progression.  
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MATERIALS AND METHODS 
Cell lines: We used the Min6 mouse insulinoma cell line (AddexBio) which was 
previously characterized for its ability to secrete insulin.8 Min6 cells were cultured in 
15%FBS DMEM media containing penicillin-streptomycin and 0.05mM 2-
mercaptoethanol. Min6 media containing 0.5mM palmitate was used for free fatty acid 
challenge. 0.5mM palmitate media was prepared by first dissolving free fatty acid (FFA)-
free BSA (Fisher Scientific) in Min6 media to a final concentration of 600uM, then 
adding sodium palmitate (Sigma). This solution was then incubated at 50°C and shaken 
overnight at 250rpm, then filtered before use.  
 
Adenoviral Vectors: Dominant negative FoxO1 adenovirus (DN256) and constitutively 
active FoxO1 (FoxO1-ADA) have been previously described.76 shCyb5r3 adenovirus, 
containing the effective shRNA sequence of 5’- GATTGGAGACACCATTGAAT -3’, was 
generated by cloning the shRNA sequence into the pEQU6-vector with LR Clonase II 
enzyme (Invitrogen) and ligating it to a pAd-REP plasmid that contained the remaining 
adenovirus genome. The recombination products were transformed into E. coli cells. 
After incubation overnight, the positive clones were selected, and cosmid DNA was 
purified. The purified cosmid DNA (2 µg) was digested with Pac1 and then transfected 
into 293 cells with Lipofectamine 2000 according to manufacturer’s instructions. The 
293 cells were grown at 37°C with 5% CO2. The adenovirus plaques were seen 7 days 




Mice: Genotyping was performed as previously described for RIP-Cre+ FoxO1/3/4-
floxed mice, Glut4-Cre+ Insulin Receptor KO, and leptin receptor-deficient Db/db mice.1, 
58, 59 RIP-Cre+ mice (Jackson Laboratories) were crossed with Cyb5r3-floxed mice 
(Knockout Mouse Project) to generate RIP-Cre+ Cyb5r3-floxed mice and were 
maintained on a C57BL/6 background. The floxed Cyb5r3 allele was genotyped using 
the primers 5’-ACAGTCCAGCTTTGGCTTTACCC-3’ and 5’- 
ATAGGGCTAGAAAAGGAGCAGAGAGC-3’ yielding a 456bp product. We derived Cre+ 
controls from the same litters. Sample size calculations were based on the variance 
observed in prior experiments.10, 31 All mice were fed normal chow (NC) except where 
stated otherwise, and maintained on a 12–hour light–dark cycle (lights on at 7 AM). NC 
had 62.1% calories from carbohydrates, 24.6% from protein and 13.2% from fat 
(PicoLab rodent diet 20, 5053; Purina Mills); high fat diet (HFD) had 20% calories from 
carbohydrates, 20% from protein and 60% from fat (D12492; Research Diets). The 




We performed intraperitoneal glucose tolerance tests (ipGTT) by injecting glucose (2 
g/kg) after an overnight (16h) fast, and we performed intraperitoneal insulin tolerance 
tests by injecting insulin (0.75 units/kg) after a 5h fast.118, 119 We measured insulin by 
ELISA (Mercodia). We performed hyperglycemic glucose clamps as previously 
described.10  We measured body composition by NMR (Bruker Optics). For 
determination of nonesterified fatty acids and triglycerides, we used commercially 
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available colorimetric assays (for NEFA: Wako; and for TG: Thermo Scientific). 
 
Islet Isolation and Fluorescence-Activated Cell Sorting: We isolated islets by 
collagenase digestion from mice as previously described.10 Sorting of β  cells was 
performed as previously described.113 Briefly, we incubated cells with the fluorescent 
ALDH substrate BODIPY™-aminoacetaldehyde (Aldefluor) for 1 hr prior to flow 
cytometry. Thereafter, cells were applied to a BD Influx sorter and analyzed with a BD 
LSRII instrument. We gated cells for RFP (red) and aldefluor (green) fluorescence, 
yielding three sub-populations: RFP–ALDH– (non-β cells), RFP+ALDH– (β cells), and 
RFP+ALDH+ (ALDH-positive β cells).  
 
Glucose-stimulated insulin secretion (GSIS) assays: 
For insulin secretion assays, we placed islets in ice-cold Krebs buffer (119 mM NaCl, 
2.5 mM CaCl2, 1.19 mM KH2PO4, 1.19 mM Mg2SO4, 10 mM HEPES (pH 7.4), 2% BSA 
and 2.8 mM glucose) and incubated at 37 °C for 1hr. We then stimulated islets with 
varying glucose concentrations (2.8, 16.8 mM) and secretagogues (L-Arginine (30mM), 
KCl (40mM)) for 1hr at 37 °C. At the end of the incubation, we collected islets by 
centrifugation and assayed the supernatant for insulin content by radioimmunoassay.118, 
120 Insulin levels were then normalized to total protein or total insulin content. To assay 
insulin secretion in adherent Min6 cells, we used the same protocol but with an 
overnight pre-incubation period in low (2.8mM) glucose media. 
 
Single-Cell Intracellular Calcium Microfluimetry: 
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Primary islets were isolated from RIP-Cre+:Cyb5r3fl/fl (B-Cyb5r3) mice and their controls 
then allowed to rest overnight in RPMI media containing 15% FBS and penicillin-
streptomycin. Islets were then treated with shScramble or shCyb5r3 adenovirus at 6 x 
108 PFU/10cm dish of islets, with each dish containing islets from a single mouse 
(~150-200 islets). After overnight incubation at 37°C, the islets were washed with 
RPMI+15% FBS, then allowed to rest for an additional day, allowing for expression of 
the adenoviral construct. The next day, islets were dispersed to single cells using 
trypsin digestion in a 37°C water bath, and then plated on 35mm glass bottom dishes 
with 20mm microwells pre-coated with fibronectin (Sigma, F1141). Cells were allowed to 
attach overnight, then loaded in the dark with fura2-AM (5 µM) in KRBH buffer. The cells 
were washed and then transferred into a perifusion chamber placed in the light path of a 
Zeiss Axiovert fluorescence microscope (Zeiss, USA), and perifused with low glucose 
(2.8mM), high glucose (16.8mM), or KCl (40mM) -containing KRBH buffer. β  cells were 
excited by a Lambda DG-4 150 Watt xenon light source (Sutter, Novato, USA), using 
alternating wavelengths of 340 and 380 nm at 0.5 s intervals, and imaged at 510 nm. 
For each data set, regions of interest corresponding to the locations of 10-20 individual 
cells were selected and digital images were captured using an AxioCam camera 
controlled by Stallion SB.4.1.0 PC software (Intelligent Imaging Innovations, USA). 
Single-cell intracellular Ca2+ mobilization data consisted of excitation ratios (F340/F380) 
plotted against time (min). 
 
Lactate measurement:  Lactate levels were measured by a commercially available kit 
according to manufacturer’s instructions (Abcam, Ab65331). In brief, Min6 cells were 
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washed, homogenized, and the supernatant collected. Ice-cold perchloric acid (4M) was 
added to each sample to a final concentration of 1M. Samples were incubated on ice for 
5 min. then spun down at 13,000 x g for 2 min at 4°C. Following neutralization with 
KOH, the supernatant was collected for colorimetric assay (read at 450nm).  
 
NAD+/NADH measurement: NAD+ and NADH levels were quantified by commercially 
available kit according to the manufacturer’s instructions (BioVision). In brief, cells were 
lysed by freeze/thaw. To determine NADH levels, samples were heated at 60°C for 30 
min to decompose NAD. For the detection of total NAD, samples were incubated with 
the NAD cycling enzyme mix to convert NAD+ to NADH. Both samples were then mixed 
with NADH developer and incubated at room temperature for 1h before colorimetric 
reading absorbance at 450 nm. NAD levels were calculated by subtracting NADH from 
total NAD.  
 
Reactive Oxygen Species (ROS) Measurement:  Levels of intracellular ROS were 
measured in Min6 cells by conversion of the acetyl ester CM-H2DCFDA into a 
fluorescent product (excitation/emission 485nm/520nm). Min6 cells were grown in 24-
well plates and washed once with warm Hanks buffered salt solution (HBSS). 
Immediately before the assay, 50ug of CM-H2DCFDA was reconstituted in 8.6ul DMSO 
to make a 10mM stock solution. The HBSS was then replaced with 0.8ml HBSS 
containing 1uM CM-H2DCFDA and incubated at 37°C for 30 min. The plate was then 
placed on ice and all wells were washed with cold HBSS. Cells were then scraped in 
0.5ml of cold HBSS and 200ul of the cell suspension was loaded into a black uncoated 
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96-well plate for reading. The remainder of the sample was used to assay for total 
protein (BCA protein assay kit, Pierce) to correct for total cellular content per well.  
 
Mitochondrial Complex Activity Assays: Complex I-IV activity was measured as 
previously described, with some modification detailed below.121 Mitochondrial-enriched 
fractions were used for all assay measurements. For Complex I activity, mitochondrial 
preparations were resuspended in NADH dehydrogenase assay buffer (1X PBS, 0.35% 
BSA, 200µM NADH, 240µM KCN, 60µM DCIP, 70µM decylubiquinone, 25µM Antimycin 
A) containing 200µM Rotenone or water. Complex I activity was measured as the rate of 
decrease in absorbance at 600nm.  Specific Complex I enzyme activity was calculated 
by subtracting the rotenone resistant activity from the total enzyme activity. For 
Complex II activity, mitochondrial preparations were resuspended in succinate 
dehydrogenase assay buffer (25mM K3PO4 pH 7.2, 0.35% BSA, 2mM EDTA, 5mM 
sodium succinate, 60µM DCIP, 25µM Antimycin A, 240µM KCN, 2µM Rotenone and 
150µM phenazine methosulfate). Complex II activity was measured as the rate of 
decrease in absorbance at 600nm. Complex III activity was measured as described 
previously.121 For Complex IV activity, mitochondrial preparations were resuspended in 
cytochrome C oxidase assay buffer (20mM K3PO4 pH 7.2, 0.35% BSA, 1mM EDTA, 
25µM Antimycin A, 100µg/mL reduced cytochrome C) containing either 10mM KCN or 
water. Complex IV activity was measured as the rate of decrease in absorbance at 
550nm. Specific Complex IV enzyme activity was calculated by subtracting the KCN 
resistant activity from the total enzyme activity. For each assay, absorbance was 
measured at the given wavelength every 10 sec for 20 min at 25°C using a SpectraMax 
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Paradigm Multi-Mode Microplate Reader (Molecular Devices LLC., Sunnyvale, CA). 
Enzymatic activities were normalized to protein concentrations, as determined with a 
Bradford Protein Assay Kit (Bio Rad-Laboratories, Hercules, CA) following manufacturer 
protocols. Enzyme activity was calculated using previously described equations.121 
 
Chromatin Immunoprecipitation (ChIP) Assay: ChIP was performed as described 
previously by Son et al., 2013.122 Briefly, Min6 cells were cross-linked, lysed, and 
sonicated.  Immunoprecipitation reactions were set up using 4 µg of anti-Foxo1 or IgG 
antibody per immunoprecipitation. The immunocomplexes were recovered with protein 
G-dynabeads, washed under stringent conditions and reverse-crosslinked. The 
precipitated DNA was analyzed by quantitative PCR using primers for mCyb5r3 (F: 5’- 
CATCTAGTGGAATGGGTACGTG -3’, R: 5’- TAGTGCAGAACGGTCTTTGTAG -3’).  
 
Immunoblot and Immunohistochemistry: We performed immunoblotting and 
immunohistochemistry as previously described.9 Antibodies used are listed with 
supplementary information.  
 
Mitochondrial Function: We used the XF24-3 respirometer (Seahorse Bioscience) 
with 24-well plates. We used the F1F0 ATP synthase inhibitor oligomycin to assess 
uncoupling, FCCP to estimate maximum respiration, and rotenone to measure non-
mitochondrial respiration.61  
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RNA Measurements: We used standard techniques for mRNA isolation and SYBR 
green quantitative PCR. Primers for mCyb5r3 were: (F: 5’- 
CAGGGCTTCGTGAATGAGGAG -3’, R: 5’- TCCACACATCAGTATCAGCGG -3’). All 
other PCR primer sequences have been published.9 
 
Statistical Analyses and General Methods. Sample sizes were estimated from 
expected effect size based on previous experiments. No randomization or blinding was 
used. We present data as means ± SEM. We used two-tailed Student’s t-test, one-way 
ANOVA, or two-way ANOVA for data analysis, and the customary threshold of p <0.05 




Cyb5r3 expression decreases in diabetic islets in a FoxO1-dependent 
manner 
During the progression of β-cell failure, FoxO1 is first activated in response to metabolic 
stress, and then becomes gradually inactivated.8 Subsequently, we have proposed that 
Cyb5r3 is a marker of dedifferentiating β-cells with a bimodal regulation.113 It’s induced 
in stressed β-cells with active FoxO1, and decreased in dedifferentiating β-cells when 
FoxO1 levels fall, as defined by increased Aldh1a3 activity (ALDHhi).113 To test this 
model, including the dependence of Cyb5r3 on FoxO1, we measured Cyb5r3 levels 
under different metabolic conditions. As observed previously, Cyb5r3 mRNA levels were 
induced in Aldhhi β-cells, whereas this induction was blunted in Aldhhi β-cells from Foxo1 
knockout mice (Fig. 6a). Moreover, when Cyb5r3 expression was assessed by 
immunohistochemistry of pancreatic tissue, it was reduced in multiple models of murine 
diabetes, including β cell-specific FoxO knockout,10 diabetic GIRKO,1 high fat diet 
(HFD)-fed, and S961 insulin receptor antagonist-treated mice123 (Fig. 6b, Supp. Fig. 1a-
c). 
We next tested whether Cyb5r3 is a FoxO1 target. Chromatin 
immunoprecipitation (ChIP) with an anti-FoxO1 antibody showed enrichment at a 
putative FoxO1 binding site (5’-ATAAACA-3’, position -661 to -667) in the Cyb5r3 
promoter (Fig. 6c). To assess the effect of FoxO1 activity on Cyb5r3 expression in β-
cells, we treated mouse insulinoma (Min6) cells with adenovirus encoding a 
constitutively active (FoxO1-ADA) or dominant negative (FoxO1-DN256) FoxO1.124 
Constitutively active FoxO1 caused a ~5-fold increase in Cyb5r3 expression, while 
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dominant negative FoxO1 suppressed it by 60% (Fig. 6d). These data indicate that 
FoxO1 can directly activate Cyb5r3 expression. 
 
Chapter II, Figure 6 
 
 
Cyb5r3 maintains β-cell secretory function 
To determine whether Cyb5r3 is required for proper β-cell function, we treated Min6 
cells with adenovirus expressing a short hairpin RNA against Cyb5r3 (Ad-shCyb5r3). 
The shRNA effectively lowered Cyb5r3 mRNA and protein by 95%, and 80%, 
respectively, without affecting Cyb5r4 expression (Supp. Fig. 2a-d).  We then assessed 
glucose-stimulated insulin secretion. Min6 cells treated with shCyb5r3 adenovirus 
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showed an impaired insulin secretory response compared to control cells treated with 
shScramble adenovirus (Fig. 7a). Because Cyb5r3 is thought to participate in 
mitochondrial function, we measured basal respiration, and showed that Min6 cells 
stably expressing the shCyb5r3 construct had a ~25% decrease in basal respiration 
(Fig. 7b). 
The second phase of insulin secretion in response to glucose requires 
mitochondrial  ATP production.125 Although Cyb5r3 can affect mitochondrial ETC 
activity, the mechanism by which it does so is unclear.87, 116 It can alter the availability of 
NADH for electron transfer, pass reducing equivalents to coenzyme Q, or reduce 
cytochrome b protein subunits or heme groups located in ETC complex III.2 Thus, we 
sought to determine whether loss of Cyb5r3 activity in β-cells affects ETC activity 
through complex III, or whether it had a broader impact on all ETC complexes. 
Enzymatic assays for complexes I-IV revealed that mitochondria isolated from Ad-
shCyb5r3-treated Min6 cells had 4-15% reduced activity in complexes I, II, and IV, and 
a much more severe ~50% decrease in complex III activity (Fig. 7c-f). These data are 
consistent with a primary effect of Cyb5r3 on complex III, with lesser effects facilitating 
efficient electron flux through the other complexes. 
We have proposed that a constitutive increase in β-cell lipid oxidation paves the 
way for β-cell failure and dedifferentiation, possibly by increasing ROS formation.10, 113 
ETC complexes I and III are the major producers of mitochondrial ROS, and production 
of ROS at these sites is increased in states of stymied electron flow.126 Because we 
observed that complex I and III activities were affected by shCyb5r3 treatment, we 
tested the effect of shCyb5r3 knockdown on lipid-induced ROS formation. To do this, 
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we measured ROS production in Ad-shCyb5r3-treated Min6 cells cultured with and 
without palmitate, a condition that increases fatty acid oxidation and mimics the 
metabolic inflexibility of failing β-cells. Consistent with our hypothesis, an increase in 
ROS generation was only observed when Min6 cells expressing Ad-shCyb5r3 were 
treated with 0.5mM palmitate (Fig. 7g).  
Cyb5r3 is an NADH-dependent oxidoreductase, and loss of its activity can 
perturb cellular NAD:NADH ratios. Min6 cells treated with Ad-shCyb5r3 had a decrease 
in NAD:NADH ratio, while overexpression of Cyb5r3-GFP led to an increase, consistent 
with Cyb5r3’s NADH-consuming activity (Fig. 7h,i). Furthermore, we hypothesized that 
upon knockdown of Cyb5r3, β-cells would compensate for increased NADH 
concentrations (or decreased NAD:NADH ratio) by increasing lactate production via 
lactate dehydrogenase to convert excess NADH to NAD+. Indeed, Ad-shCyb5r3-treated 
Min6 cells showed increased lactate levels when cultured in 0.5mM palmitate (Fig. 7j). 
In the setting of increased β-cell lipid oxidation, the disturbances in NAD:NADH ratio, 
combined with increased ROS production and reduced electron transport, may generate 
enough cellular stress so as to induce β-cell failure. 
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Chapter II, Figure 7 
 
 
Cyb5r3 is necessary for islet insulin secretory function ex vivo 
Although we observed defects in glucose-stimulated insulin secretion in Min6 cells with 
Cyb5r3 knockdown, it remained unclear whether Cyb5r3 played a similar critical role 
A B C 
D E F 
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within the islet. To test this point, we isolated primary islets from wildtype mice, treated 
them with shCyb5r3 or shScramble adenoviruses, then performed ex vivo glucose-
stimulated insulin secretion assays. Consistent with findings in Min6 cells, Ad-shCyb5r3-
treated islets displayed blunted insulin secretion in response to glucose that was not 
due to differences in insulin content (Fig. 8a,b).  
To examine whether loss of Cyb5r3 impinges on processes upstream or 
downstream of intracellular calcium release, we performed single-cell Fura2AM calcium 
flux imaging on β-cells exposed to glucose and KCl. To chemically identify β-cells, we 
isolated islets from Insulin2-GFP mice74, dissociated to single cells, treated with Ad-
shCyb5r3 or Ad-shScramble, then gated single β-cells by GFP-expression for 
fluorescence measurements. Remarkably, Ad-shCyb5r3-treated β-cells displayed a 
severely blunted calcium flux in response to glucose and, to a lesser extent, KCl (Fig. 
8c,d). Given the in vitro data supporting Cyb5r3’s role in ETC function, these findings 
suggest that Cyb5r3 is required for efficient ATP production from glucose. 
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Chapter II, Figure 8 
 
 
β-cell dysfunction following Cyb5r3 ablation in mice 
To examine the effects of the loss of Cyb5r3 in β-cells in vivo, we generated rat 
insulin promoter (RIP)-Cre-Cyb5r3fl/fl mice (B-Cyb5r3). These mice were born at 





mass, fat mass, or tissue water content (Supp. Fig. 3a). Immunostaining for Cyb5r3 in 
pancreas sections of B-Cyb5r3 mice revealed 80-100% Cre recombinase efficiency, 
consistent with previous findings (Fig. 9a).9 Notably, Cre recombinase efficiency was 
less in male mice, with some islets still retaining Cyb5r3 expression in the majority of β-
cells (Supp. Fig. 4a). Islets from 2-month-old B-Cyb5r3 mice had normal β and δ/PP cell 
ratios (quantified together) compared to RIP-Cre+ controls (Supp. Fig. 5a). However, B-
Cyb5r3 islets had a greater proportion of α cells compared to controls (17% vs. 11% of 
total islet area, p=0.032) (Fig. 10b, Supp. Fig. 5a).  
	 63	
Chapter II, Figure 9 
 































Chapter II, Figure 9 Continued 
 
 





















Chapter II, Figure 10 
 































Chapter II, Figure 10 Continued 
 





















 Chapter II, Figure 11 
 
A B C 
D E F 
G H I 
	 68	
Chapter II, Figure 12 
 
 
We analyzed the metabolic features of B-Cyb5r3 mice. Although plasma glucose 
levels in 4-month-old animals were normal, females demonstrated glucose intolerance 







(IPGTT), as well as lower refed insulin levels after a 4-hour fast (Fig. 11a,c). Male mice 
did not display glucose intolerance at 4 months of age, but showed mild glucose 
intolerance at 8 months of age (Fig. 11b, Supp. Fig. 4b). We observed similar results in 
oral glucose tolerance tests (OGTT), effectively ruling out an incretin effect (Supp. Fig. 
3c,d). In contrast, insulin tolerance tests, fasting or re-fed free fatty acids, and 
triglyceride levels revealed no differences between B-Cyb5r3 and control mice (Fig. 
11d,e, Supp. Fig. 3e,f).  
Next, we tested the effects of diet on B-Cyb5r3 animals. Within 1 week of being 
placed on a diet consisting of 60% fat (HFD), female B-Cyb5r3 mice began to exhibit 
significant hyperglycemia (Fig. 11f). Glucose tolerance tests confirmed that 4-month-old 
female B-Cyb5r3 mice on HFD develop glucose intolerance relative to controls (Fig. 
11g,h). By 6 months of age, both male and female mice showed impaired insulin 
secretion 15 minutes after a glucose gavage (Fig. 11i). To directly assess insulin 
secretory function in vivo, we performed hyperglycemic clamps. B-Cyb5r3 mice required 
a lower glucose infusion rate to maintain hyperglycemia and had a commensurate 
decrease in plasma insulin levels, suggestive of a primary insulin secretory defect (Fig. 
12a-f). 
We next analyzed islet composition and markers of β-cell functional maturity. 
Interestingly, islets from 2-month-old B-Cyb5r3 mice showed decreased expression of 
Glut2 and MafA (Fig. 9c,d), but preserved expression of Pdx1, suggesting that β-cells 
partly maintain their differentiated features (Fig. 9e). However, in 6-month-old B-Cyb5r3 
animals islet architecture was disrupted, with α− and δ/PP-cells appearing in the islet 
core (Fig. 10a), and the greater relative proportion of α-cells persisted (Supp. Fig. 5b). 
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In addition to the previously established lack of Glut2 and MafA (Fig. 10b,c), the majority 
of β-cells now showed a substantial decrease in Pdx1 expression (Fig. 10d). We also 
investigated FoxO1 expression and localization. As expected based on the incipient 
hyperglycemia, there was increased nuclear FoxO1 staining in B-Cyb5r3 islets (Fig. 
10e). However, this increase didn’t result in improved expression of β-cell differentiation 
markers, such as MafA and Pdx1. These data indicate that B-Cyb5r3 is required for 
FoxO1 induction of MafA (the relationship between FoxO1 and Pdx1 being more 
complex), and suggest that the β-cell’s redox status or mitochondrial function regulates 
MafA. These data indicate that B-Cyb5r3 β-cells are trying to compensate for impaired 
function by increasing FoxO1 activity, but since they lack Cyb5r3 they are unable to do 
so. 
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Chapter II, Figure 13 
 
Impaired islet function in B-Cyb5r3 mice 
To assess islet function in B-Cyb5r3 mice, we isolated primary islets and 
performed glucose-stimulated insulin secretion assays. Consistent with data from Min6 
cells and islets treated with Ad-shCyb5r3, B-Cyb5r3 mouse islets showed decreased 
insulin secretion in response to glucose compared to RIP-Cre+ controls, as well as a 
blunted response to the depolarizing agents L-arginine and KCl (Fig. 13a,b). To 




we assessed basal respiration in B-Cyb5r3 primary islets and found a nearly ~50% 
decrease compared to controls (Fig. 13c). Thus, the data indicate that lack of Cyb5r3 




The paramount challenge in defining the progression of β cell dedifferentiation 
has been identifying molecular pathways that contribute to the clinically silent, or 
reversible, phase of pathogenesis. What events initiate the slow creep to 
hyperglycemia, and at what point do β cells begin to lose their “β cell-ness”? Answering 
these questions is essential for the development of therapeutics aimed at the prevention 
or reversal of dedifferentiation. Current literature continues to characterize 
dedifferentiation as the loss of classical β cell markers such as Insulin, FoxO1, MafA, 
Nkx6.1, and Pdx1, or conversely, as the acquisition of progenitor markers such as 
Neurogenin3, L-Myc, Nanog, and Oct4.9, 44, 46, 99 Some degree of temporal resolution 
has been achieved as to the order of transcription factor downregulation. For example, 
in db/db mice, FoxO1 nuclear translocation occurs at 6 weeks of age, while depletion of 
MafA and Glut2 occurs at 8 weeks, followed by Nkx6.1 at 10 weeks.99 Although the loss 
of these transcription factors acts as landmarks on the path to β cell dedifferentiation, it 
is not clear why one precedes another, or perhaps more importantly, how one may 
beget another. From a therapeutic standpoint, we still don’t know which downstream 
effectors are critical contributors to targetable cellular processes in β cell function. 
To address this question, we identified a marker of β cell dysfunction that could 
be used to isolate and study the early phase of dedifferentiation. Using the FoxO β cell 
conditional knockout mouse (β-FoxO), a MODY-like murine model of diabetes known to 
display β cell dedifferentiation with age,10 we found that expression of Aldh1a3 was 
uniquely increased in dysfunctional β cells.113 RNA sequencing of the Aldh1a3+ β cell 
population then identified Cyb5r3 as the top down-regulated gene. 
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The key contribution of this work is the identification of Cyb5r3 as a novel FoxO1-
regulated oxidoreductase that is essential to β cell function. In vitro, β cells with Cyb5r3 
knockdown display impaired glucose-stimulated insulin secretion, decreased basal 
respiration, impaired mitochondrial complex activity, decreased NAD:NADH ratio, and 
increased ROS production. Ex vivo, primary islets with Cyb5r3 knockdown also 
displayed impaired glucose-stimulated insulin secretion and impaired calcium flux in 
response to high glucose. Mice with β cell-specific Cyb5r3 deletion show impaired 
glucose tolerance and blunted insulin secretion, the onset of which is hastened by high 
fat diet feeding. Islets from B-Cyb5r3 mice have impaired glucose stimulated insulin 
secretion, decreased basal respiration, and loss of the mature β cell markers Glut2, 
MafA, and Pdx1. Both in vitro and in vivo findings suggest that loss of Cyb5r3 causes 
profound mitochondrial dysfunction. Therefore, Cyb5r3 acts as a potential mechanistic 
link between the loss of FoxO, cellular stress, and dedifferentiation.  
 
Mitochondria are critical fuel sensors in β cells that allow the coupling of nutrient 
metabolism with insulin secretion. Their essential role in β cell metabolism-secretion 
coupling is evidenced by the maternally-inherited mutations in mitochondrial DNA that 
are known to cause functional impairment of the ETC and insulin-deficient forms of 
diabetes.127, 128 Perhaps unsurprisingly then, mitochondrial dysfunction has been found 
in many rodent models of diabetes and in human patients.10, 113, 127, 129-131 In particular, β 
cells are susceptible to ROS damage because they produce relatively low levels of the 
free-radical quenching enzymes superoxide dismutase, catalase, and glutathione 
peroxidase.39, 132, 133 The mitochondrial genome, inner membrane proteins (such as ATP 
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synthase), and inner membrane lipids are especially vulnerable to oxidative damage 
due to their proximity to free radicals. Oxidation of the mitochondrial membrane lipid 
cardiolipin has been shown to alter the activity of adenine nucleotide transporter and 
cytochrome c oxidase, both of which are critical to ATP synthesis and insulin 
secretion.134 Furthermore, in alveolar epithelial cells, mitochondrial complex III-
generated ROS has been shown to induce cell death through the activation of ASK1-
JNK pathways.135 Our findings show that deletion of β cell Cyb5r3 causes impaired 
mitochondrial complex activity and increased ROS production, reducing glucose-
stimulated insulin secretion and predisposing to β cell failure in B-Cyb5r3 mice. The 
decrease in mitochondrial complex activity we observe could be due to a direct effect on 
electron transport (i.e. through the production of reducing equivalents), or an indirect 
effect via the assembly of ETC complexes, as Cyb5r3’s flavin domain is known to 
reduce heme groups which are found in the cytochrome b and cytochrome c subunits of 
Complex III, as well as in Complex IV.136 In light of these data, we propose the following 
model: in the setting of incipient metabolic stress, β cell FoxO1 translocates to the 
nucleus to initiate a protective response.8 As a part of this repertoire, Cyb5r3 expression 
is increased to facilitate electron transport, ATP production, antioxidant reduction, and 
to shunt excess fatty acyl-CoA away from the oxidative pathway. However, as 
previously shown, FoxO1 is eventually degraded with chronic stress, leading to a 
concomitant decrease in Cyb5r3 expression.9 Therefore, loss of Cyb5r3 activity with 
subsequent mitochondrial dysfunction may initiate a cycle of impaired stimulus-
secretion coupling, worsened hyperglycemia, and increased biosynthetic demand for 
insulin, eventually causing the loss of β cell function and identity. 
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There are many parallels between the β-FoxO and B-Cyb5r3 models. Islets from 
both show impaired glucose-stimulated insulin secretion and loss of mature β cell 
markers MafA, Glut2, and Pdx1 before the onset of β cell dedifferentiation as defined by 
expression of endocrine progenitor markers.9, 113 At a cellular level, both knockout 
models display defects in mitochondrial respiration and glucose-stimulated calcium flux 
and in mice, glucose intolerance occurs in adulthood and worsens with age.10 These 
similarities suggest that the mitochondrial phenotype observed in β-FoxO knockouts is 
driven by the loss of Cyb5r3, and that restoration of Cyb5r3 in β-FoxO mice might 
prevent the β cell dedifferentiation observed with aging and multiparity. 
Cyb5r3 is expressed in nearly all tissues and has been implicated in a wide 
range of cellular redox reactions.87 The yeast ortholog of Cyb5r3, NADH-Coenzyme Q 
reductase 1 (NQR1), reduces fasting-induced apoptosis by increasing levels of reduced 
Coenzyme Q and extends lifespan through a SIR2-dependent mechanism that 
increases oxidative metabolism.95 Yeast NQR1 activity increases in calorie restriction, a 
condition usually accompanied by increased FA oxidation. In mammals, Cyb5r3 is 
localized predominantly to mitochondrial and endoplasmic reticulum membranes and 
plays a role in many cellular processes, including the reduction of cytochrome b5 and 
coenzyme Q, fatty acid desaturation/elongation, cholesterol biosynthesis, metabolism of 
xenobiotics, and antioxidant reduction, making it likely that it contributes to β cell 
function in multiple ways. Mice with global overexpression of Cyb5r3 have moderate 
lifespan extension, increased insulin sensitivity, increased complex I and III activity, a 
greater proportion of unsaturated very long chain FAs in TGs, and reduced ROS 
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production.116 It is still unknown whether β cells from these mice are protected from 
dedifferentiation. 
Although our study has focused on Cyb5r3’s role in the mitochondria, it is likely 
that cellular lipid compositions are altered in B-Cyb5r3 mice, which in itself can impair 
the function of critical organelles, such as the ER and mitochondria.137, 138 Cyb5r3’s lipid 
desaturation/elongation function may also stimulate triglyceride synthesis and shunt free 
fatty acid metabolism away from toxic lipid species such as ceramide. As mechanistic 
precedence, Min6 cells with higher expression of stearoyl-CoA desaturase 1 (SCD1), 
the rate-limiting enzyme in the formation of monounsaturated fatty acids, are protected 
from lipid-induced toxicity.139 
Cyb5r3’s role in reducing antioxidants such as coenzyme Q, α-tocopherol, and 
ascorbate may be especially critical in oxidative stress-prone β cells. In response to 
oxidative stress, FoxO1 protects against β cell failure by translocating to the nucleus 
and inducing expression of NeuroD and MafA, two transcription factors regulating the 
Insulin2 gene.8 However, with prolonged stress or hyperglycemia, the loss of FoxO1-
dependent Cyb5r3 expression may hasten the depletion of what little antioxidant 
reserves remain. It is known that Cyb5r3 expression can be stimulated by oxidative 
stress: binding of the activating transcription factor Nrf2 (in complex with FoxO3a) to two 
antioxidant response elements in the human Cyb5r3 promoter is increased by exposure 
to diquat.87 In our study, Min6 cells with Cyb5r3 knockdown showed increased ROS 
production only when exposed to the fatty acid palmitate. These findings suggest that 
Cyb5r3’s role in reducing antioxidants may be a safeguard against conditions that 
increase mitochondrial free radical production. 
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Clinical guidelines for the treatment of diabetes continue to reinforce the 
importance of “β cell rest.” 7, 53, 54 In patients with type II diabetes, early intensive insulin 
therapy has been shown to improve β cell function, glycemic control, and lower 
remission rates, consistent with a model in which β cells dedifferentiate then 
redifferentiate upon recovery.140 It is our hope that as the progression of β cell identity 
loss continues to be mapped out, more molecular targets amenable to pharmacological 
intervention will arise. The results of this study suggest that Cyb5r3 may be one such 
target and that therapies that improve mitochondrial plasticity and optimize ETC function 
may be particularly beneficial for the prevention of β cell dedifferentiation. Membrane 
permeable peptides that target cardiolipin on the inner mitochondrial membrane to 
facilitate electron transfer from cytochrome c to complex IV are currently in clinical trials 
for multiple indications ranging from congestive heart failure to Leber’s Hereditary Optic 
Neuropathy.141 Although the effect of this type of intervention on β cell failure remains 
unknown, these peptides have been shown to improve the function of aged islets post-
transplantation and to facilitate the transplant of islets by preserving mitochondrial 
polarization and reducing islet cell apoptosis.142 The discovery of such peptides 
highlights the possibility that a novel class of mitochondrial therapeutics may be able to 
selectively enhance ETC complex functions as a way to prevent β cell dedifferentiation. 
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CHAPTER II SUPPLEMENTARY INFORMATION 
Chapter II, Supplemental Figure 1
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Chapter II, Supplemental Figure 4
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Chapter II, Supplemental Table 1 
Antigen Species Dilution Product Number Company 
Insulin Guinea Pig 1:2000 A0564 DAKO 
Aldh1a3 Rabbit 1:100 NBP2-15339 Novus 
Cyb5r3 Rabbit 1:100 10894-1-AP Proteintech 
Proglucagon Rabbit 1:500 #8233 Cell Signaling 
Somatostatin Goat 1:1000 SC-7819 Santa Cruz 
Pancreatic Polypeptide Goat 1:500 AB77192 Abcam 
Glut2 Rabbit 1:200 AB54460 Abcam 
MafA Rabbit 1:200 IHC00352 Bethyl 
Pdx1 Goat 1:100 AF2419 R&D 
FoxO1 Rabbit 1:100 CST 2880S Cell Signaling 












CONCLUSIONS AND FUTURE DIRECTIONS 
Chapter I described the characterization of Aldh1a3 as a marker of dysfunctional β-
cells. Identification of the top differentially-regulated transcripts in murine models of 
diabetes characterized by dedifferentiation (ie Pdx1-FoxO KO and β-FoxO KO mice) 
showed an increase in Aldh1a3 expression. Quantification of transcript, protein, and 
retinoic acid species confirmed that Aldh1a3 was induced in diabetic islets. Moreover, 
by immunohistochemistry, Aldh1a3-high cells were found to have lower expression of 
MafA, Nkx6.1, Insulin, but higher expression of the progenitor markers L-myc and Ngn3.  
 
Treatment of β-cells with Aldefluor allowed for the isolation of β-cells based on their 
aldehyde dehydrogenase activity. Comparison of insulin secretion in Aldh-low and Aldh-
high populations revealed that Aldh-high β-cells have a functional defect in insulin 
secretion. RNA sequencing was performed on these populations from RIP-Cre+ control 
and β-FoxO mice. In both genotypes, the Aldh-high population was characterized by the 
sole induction of the Aldh1a3 isoform (and not other Aldh enzymes), as well as defects 
in oxidative phosphorylation and mitochondrial function.  
 
To assess whether increased Aldh1a3 activity alters β-cell function, we overexpressed 
Aldh1a3 in Min6 cells by adenoviral infection. These cells showed no change in insulin 
secretion, leading us to the tentative conclusion that Aldh1a3 was solely a marker of 
dysfunction, rather than a contributor. From these data, we conclude that Aldh1a3 is a 
marker of dysfunctional β-cells characterized by the loss of mature β-cell markers, the 
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expression of endocrine progenitor markers, and an insulin secretory defect likely due to 
mitochondrial dysfunction.  
 
Additional studies are required to determine whether Aldh1a3 induction has a functional 
role in the failing β-cell. Mice with β-specific Aldh1a3 overexpression have now been 
generated and are currently being characterized. The question remains as to where in 
the progression of diabetes/dedifferentiation Aldh1a3 induction occurs. Although our 
studies placed one more signpost on the road to dedifferentiation, additional markers 
need to be identified. The loss of MafA, Insulin, and Nkx6.1 expression in Aldh-high β-
cells suggest that Aldh1a3 may not be an early marker of dysfunction, but rather a later 
marker of ongoing dedifferentiation. Co-staining of Aldh1a3 and Ngn3/L-myc in a subset 
of Aldh-high β-cells supports this hypothesis.  
 
Chapter II extended the work in Chapter I by characterizing the role of Cyb5r3 in the β-
cell. Cyb5r3 was found to be the second-most differentially regulated transcript by RNA 
sequencing in a comparison of Aldh-high β-cells from RIP-Cre+ control versus β-FoxO 
mice. Immunohistochemistry confirmed that Cyb5r3 expression is reduced in β-cells 
from multiple models of diabetes. ChIP and treatment of Min6 cells with constitutively 
active or dominant negative forms of FoxO1 confirmed that Cyb5r3 expression is 
directly activated by FoxO1.  
 
Knockdown of Cyb5r3 expression had a wide array of effects in vitro. Treatment of Min6 
cells with an shCyb5r3-expressing adenovirus showed that these cells had decreased 
	 88	
insulin secretion, basal respiration, mitochondrial complex III activity, NAD/NADH ratio, 
but increased ROS production with palmitate exposure. Ex vivo, primary islets treated 
with the same shCyb5r3 adenovirus showed impaired insulin secretion with no change 
in total insulin content, as well as impaired calcium flux in response to high glucose and 
KCl.  
 
Mice with β-cell-specific knockout of Cyb5r3 showed impaired glucose tolerance due to 
a primary β-cell defect. Hyperglycemic clamp confirmed that reduced glucose disposal 
occurred in the setting of impaired insulin secretion. Challenge with HFD feeding 
caused elevated glucose levels in female B-Cyb5r3 mice within one week. Primary 
islets from B-Cyb5r3 mice were functionally impaired, as stimulated insulin secretion 
assays revealed a blunted response to high glucose, the secretagogue l-arginine, and 
the depolarizing agent KCl. Respirometry of primary islets showed a reduction in 
respiration, consistent with the findings in shCyb5r3-treated Min6 cells. 
 
Analysis of islets by immunohistochemistry revealed that B-Cyb5r3 islets had reduced 
Glut2 and MafA expression by 2 months of age, but still retained expression of Pdx1. By 
6 months of age, Glut2, MafA, and Pdx1 expression were all decreased, and a 
compensatory increase in nuclear FoxO1 staining was observed. These findings 
suggest that Cyb5r3 is required for FoxO1’s maintenance of β-cell identity.  
 
From these data, we conclude that Cyb5r3 is the missing link between FoxO1 and 
mitochondrial function. As previously mentioned, β-cells lacking FoxO are characterized 
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by metabolic inflexibility and mitochondrial dysfunction. Although it is now clear that 
Cyb5r3 contributes to β-cell mitochondrial function, it is not known whether Cyb5r3 
plays a role in substrate selection/utilization. Culturing of shCyb5r3-treated Min6 cells in 
palmitate increases the production of ROS, but it is possible that Cyb5r3 might also 
influence pathways linked to glucose versus FFA oxidation. Alternatively, mitochondrial 
dysfunction in general might cause a preference for lipid versus glucose oxidation in the 
β-cell. 
 
It also remains unclear whether restoration of Cyb5r3 activity can rescue the 
mitochondrial dysfunction observed in failing β-cells. Future experiments could attempt 
to answer this by overexpressing Cyb5r3 in FoxO knockout Min6 cells, or by introducing 
a β-cell-specific Cyb5r3 overexpression allele into the β-FoxO mouse. In terms of 
translational relevance, there are currently no known pharmacological activators of 
Cyb5r3. However, treatment of B-Cyb5r3 or β-FoxO islets with the SS-31 peptide might 
reveal whether an improvement of ETC function can rescue the impairment in insulin 
secretion.  
 
Finally, Cyb5r3 may contribute to β-cell function independent of its role in the 
mitochondria. For example, it is unclear whether Cyb5r3’s maintenance of NAD/NADH 
ratio might influence the activity of sirtuins and protein acetylation. Cyb5r3 might also 
affect the function of multiple organelles through its lipid elongation/desaturation 
function. Loss of Cyb5r3 could lead to a preponderance of saturated phospholipids in 
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ER, plasma, or mitochondrial membranes and cause several types of organelle stress. 
These functions remain unexplored and will be addressed in future experiments. 
 
In summary, Chapter I of this thesis identifies a novel marker of dysfunctional β-cells, 
with sequencing of this dysfunctional population yielding potential contributors to  β-cell 
dedifferentiation. Chapter II validates one such contributor, Cyb5r3, an oxidoreductase 
shown to be critical to  β-cell mitochondrial function as well as FoxO1-mediated  β-cell 
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